Defining the Cerebral Cavernous Malformation Protein Signaling Network in Endothelial Cells by Dibble, Christopher F.
DEFINING THE CEREBRAL CAVERNOUS MALFORMATION PROTEIN 
SIGNALING NETWORK IN ENDOTHELIAL CELLS 
 
 
 
 
Christopher Francis Dibble 
 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel 
Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in 
the Department of Pharmacology 
 
 
 
 
Chapel Hill 
2013 
 
 
 
 
 
 
 
 
 
Approved by: 
Gary L. Johnson, Ph.D. 
Ellie Tzima, Ph.D. 
David S. Rubenstein, M.D., Ph.D. 
David P. Siderovski, Ph.D. 
Angelique W. Whitehurst, Ph.D
 ii 
ABSTRACT 
 
CHRISTOPHER FRANCIS DIBBLE. Defining the cerebral cavernous malformation 
protein signaling network in endothelial cells 
(Under the Direction of Gary L. Johnson, Ph.D.) 
 
Cerebral cavernous malformations (CCM) are cerebrovascular lesions 
occurring with homozygous loss of function mutations of CCM1, -2, and -3. CCMs 
can cause neurological deficits, seizures, and fatal hemorrhagic stroke. Loss of 
function in any one of the three CCM proteins leads to defects in in vitro 
angiogenesis assays, along with increased actin stress fibers in endothelial cells. 
Elevated RhoA and Rho kinase (ROCK)-LIM kinase hyperactivity results upon loss 
of the CCM proteins, likely from dysregulation of the E3 ubiquitin ligase SMURF1. 
Phosphorylation of the LIM kinase substrate and actin depolymerizing factor cofilin is 
increased in primary endothelial cells and surgically resected human CCM lesions, 
providing a novel biomarker for CCM disease. The CCM phenotype and RhoA-
ROCK hyperactivity can be recapitulated in endothelial progenitor-derived 
endothelial cells, primary cells that can be isolated from the peripheral blood of 
human CCM patients. Significantly, treatment with structurally distinct small 
molecule ROCK inhibitors rescues the CCM phenotype in vitro and reverses the 
hyperactivation of ROCK effectors seen with loss of the CCM proteins. Interrogation 
of the kinome in endothelial cells with CCM2 knockdown using multiplexed kinase 
inhibitor beads coupled to mass spectroscopy reveals striking dysregulation, likely 
multifactorial from loss of the scaffold-like CCM2 protein, dysregulation of SMURF1, 
and concomitant hyperactivation of the small GTPase RhoA. Of particular interest 
 iii 
are the loss of two critical angiogenesis kinases, TIE-2 and BMX. Together, these 
data provides insight to the molecular mechanism of CCM pathophysiology and 
provides clues for future successful pharmacological treatment of the disease. 
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I. Introduction 
 
Cerebral Cavernous Malformation Disease: an overview 
 Cerebral cavernous malformations (CCM; OMIM 116860) are neurovascular 
lesions caused by the bi-allelic loss of the genes CCM1, CCM2, and CCM3. Lesions 
are characterized by the loss of normal vascular architecture and gradual 
replacement by dilated, leaky capillaries (1). CCMs occur primarily in brain 
vasculature, but have been reported in numerous locations throughout the body, 
including the liver, spinal cord, and retina (2). It is unclear whether there is a 
biological reason for the substantially higher incidence of CCM in the brain, or 
whether it is a matter of increased detection, given that brain lesions are far more 
likely to cause symptoms. Patients suffer from a variety of symptoms, ranging from 
focal neurological deficits to hemorrhagic stroke. Unfortunately, therapeutic 
strategies are limited to surgical resection or radio-ablation of lesions, procedures 
that involve substantial risk to the patient. 
 
Epidemiology 
 The incidence of CCM mutation is approximately 1 in 200 for Caucasians and 
up to 1 in 70 for Hispanics (3). Overall, CCM is the second most common vascular 
lesion of the central nervous system, second only to Developmental Venous 
Anomalies/Venous Angiomas (4). Men and women are equally likely to be affected, 
 2 
with an average onset at 30 to 40 years of age, but approximately 25% of cases 
present in infancy or childhood (5-7). Development of a CCM lesion does not 
necessarily mean that patients become symptomatic, with some studies reporting 
that approximately 10-40% of patients with MRI confirmed lesions remain 
asymptomatic (4, 8). There is a familial and sporadic form of CCM, with 
approximately 10-40% of cases classified as familial in Caucasians and up to 50% 
familial in Hispanics (2, 9). However some studies suggest that a significant number 
of cases reported as sporadic are in fact familial. For example, a 1998 study by 
Labauge et al. showed that up to 75% of sporadic cases were familial (10). 
Mutations in CCM1 account for 60% of reported cases, with CCM2 and CCM3 
mutations comprising approximately 18 and 10% of cases, respectively (11, 12). In 
up to 22% of CCM cases with multiple lesions no mutation can be detected in the 
CCM genes (13). 
The high incidence of CCM1 mutation in Hispanics has been traced to a 
founder mutation (Q248X) occurring several centuries ago in Northern Mexico, in 
what is today New Mexico (14-16). While no data currently exists to support this 
speculation, the high frequency of heterozygous carriers in the general population 
suggests there may be a selective advantage to CCM heterozygosity, similar to what 
is seen with sickle cell trait. Regardless, the rapid advances in next generation deep 
sequencing will provide an increasingly comprehensive understanding of CCM 
mutation. 
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Genetics 
CCM lesions develop upon homozygous inactivating mutations in CCM1, -2, 
or -3. To date more than 150 distinct CCM mutations have been published, including 
nonsense, splice-site, and frameshift mutations, with the common theme being loss 
of CCM protein function (11, 17-22). Many CCM mutations are thought to result in 
nonsense-mediated degradation of mRNA transcripts, leading to a total loss of 
protein expression. Interestingly, the only known CCM missense mutation not 
affecting splicing is located in the C-terminal end of the phosphotyrosine binding 
(PTB) domain of CCM2, and disrupts the interaction of CCM1 and -2 (23). 
Importantly, CCM lesions are thought to develop upon bi-allelic loss of the CCM 
genes in endothelial cells, not in vascular support cells or parenchyma. Gault et al. 
reported the first bi-allelic germline and sporadic mutation in a CCM lesion in a 
patient with CCM1 mutation (24). Laser capture micro-dissection in a large number 
of surgically resected lesions demonstrated that cells in the endothelial monolayer, 
and not the surrounding brain tissue, display loss of the CCM genes (25). 
Subsequent work has affirmed this conclusion, with one exception. Louvi et al. 
recently demonstrated that conditional deletion of CCM3 in mouse astrocytes led to 
lesion formation. Given the integrated and complex signaling between astrocytes 
and endothelial cells these results seem plausible, however this work has not been 
recapitulated or demonstrated in human lesions (26). 
The genetic mechanism of CCM lesion development remains controversial, 
but the leading theory is loss of heterozygosity (LOH) resulting from a 2-hit 
mechanism. This mechanism is seen in the loss of tumor suppressor genes, with the 
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most famous example being the loss of RB in the pediatric cancer retinoblastoma 
(27). According to this hypothesis, the first hit results from a germline mutation, and 
the second hit comes from somatic mutation in familial disease, with both hits 
occurring somatically in sporadic CCM. There are several lines of evidence for the 2-
hit hypothesis, including clinical observations from human patients and molecular 
genetics performed in surgically resected lesions, as well as observations from 
Genetically Engineered Mouse Models (GEMMs). The autosomal dominant pattern 
of inheritance and multiple lesions in familial patients, and the usual solitary lesions 
seen with sporadic cases, are consistent with a 2-hit mechanism. The best study to 
date on the genetic mechanism for CCM development was by Akers et al. using 
surgically resected CCM lesion tissue to identify bi-allelic mutations in familial 
patients. After sequencing the germline mutation, somatic mutations were identified 
through repeated cycles of amplification, subcloning, and sequencing (25). Bi-allelic 
germline and somatic mutations were found in the endothelium of lesions from 
CCM1, -2, and -3 familial patients, with only single mutations being found in non-
endothelial cells. Interestingly, not all endothelial cells in the CCM lesions had 
double hits, suggesting that a mosaicism of loss of heterozygosity is sufficient to 
cause CCM pathophysiology. 
There is also compelling evidence for the 2-hit hypothesis in mouse models. 
Several mouse studies have shown that crossing ccm heterozygotes with a 
mismatch repair defective background leads to spontaneous lesion generation. This 
is significant because mice heterozygous for ccm1, -2, or -3 do not spontaneously 
develop lesions (28, 29). Plummer et al. first showed that ccm1 heterozygous mice 
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developed lesions when crossed with p53 null mice (29). More recent work showed 
that CCM lesions develop spontaneously in ccm1 heterozygous mice when bred into 
a mismatch-repair deficient background, with either homozygous deletion of the 
tumor suppressor Trp53 or the mismatch-repair gene Msh2 (28). While these mouse 
models support the LOH hypothesis for lesion development, the conclusions that 
can be drawn are limited given that there is no evidence that p53 or Msh2 play a role 
in the natural history of CCM disease. The genetic mechanism of the second hit 
remains unknown, and is perhaps the most significant question remaining in the 
CCM field, besides discovering the molecular mechanism of disease. Multiple 
hypotheses have been proposed, including an epigenetic second hit, 
uncharacterized cis-regulatory mechanisms, or stem cell or endothelial precursor 
cell mutation. 
Significantly, LOH has been demonstrated in multiple vascular diseases 
related to CCM, including Cutaneomucosal Venous Malformations (MIM 600195), 
and Capillary Malformations (OMIM 163000) (30). Bi-allelic CCM loss of function is 
embryonic lethal in mice between E8.0 and E9.5, supporting the importance of the 
CCM genes in angiogenesis, and there are no known cases of humans born with 
homozygous germline CCM mutation (31-34). One other possible mechanism for a 
second hit would be trans-heterozygosity, (e.g. heterozygous for CCM1 and CCM2) 
from a second hit in another CCM gene. Trans heterozygosity has been 
demonstrated as the cause of the second hit in several disorders, including 
Polycystic Kidney Disease (35, 36). However, in unpublished data Akers et al. 
reported that ccm trans-heterozygous mice do not develop lesions (25). 
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Furthermore, no cases have been reported of humans with trans-heterozygosity in 
CCM genes, although the possibility cannot be ruled out given that current clinical 
CCM genetic testing techniques halts after finding the first mutation. 
Finally, the discrepancy between genetic linkage data and CCM sequence 
analysis in patients has lead to the suggestion that there is a fourth, as of yet 
unidentified CCM gene. For example, one study analyzed a panel of 29 familial CCM 
patients that had tested negative for CCM1 and -2 mutation, and was only able to 
identify CCM3 mutation in 3 of them (37). There are several possible explanations 
for this, including technical challenges in sequencing CCM3 mutations, but one 
interpretation is that there is a fourth gene that can cause CCM disease. Given that 
loss of CCM1, -2, and -3 gives identical phenotypes despite little common similarities 
in protein function, it definitely seems possible that future work discovers “CCM4.”  
 
Pathology 
Upon gross examination, CCMs appear to be purple blueberry or mulberry-
like structures, and generally vary from 2mm to 2cm in diameter (1). 70 to 90% of 
CCMs are located in the cerebrum, and are most often subcortical (38, 39). 
Histologically, CCM lesions are focal, well circumscribed, highly dilated tangles of 
capillaries with an intact endothelial monolayer (Fig 1.1). Lesions can be classified 
as stage 1 (isolated dilated vessels with hemosiderin deposition) or stage 2 (clusters 
of dilated vessels with increased gliosis and calcification), with stage 2 following 
stage 1 in the natural history of the lesion (34). CCMs exhibit loss of normal vascular 
architecture, including loss of vascular smooth muscle cells and pericytes, with 
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replacement of intervening neural parenchyma with gliosis and scarification (38). 
CCM lesions are often filled with slow flowing or thrombosed blood (40). Importantly, 
lesions lack the normal tight junctions between endothelial cells and astrocytes, 
although the mechanism of this loss is unclear (41). As a result of the repeated 
blood extravasation resulting from the loss of vascular integrity in these vessels, the 
lesions are also characterized by macrophage and lymphocyte infiltration into the 
proximal parenchyma, as well as striking hemosiderin deposition (38, 42). Lesions 
are thought to evolve through their lifetime, with early stage lesions generally 
displaying a mulberry-like pattern and later stage lesions showing greater vessel 
dilation with enhanced scarring and necrosis. Generally, lesion size and burden 
increase with age (2). The evolutive nature of lesions is also supported by the 
observed tendency for de novo development of CCMs in areas of surgical or 
radiological intervention (43, 44). Because of their disorganized architecture and 
highly friable nature, as well as the fact that the thin endothelial monolayer is the 
region of interest, performing assays such as PCR or immunohistochemistry (IHC) 
on pathological specimens is challenging. Given the dearth of CCM samples, 
increased biobanking and cataloging of surgically resected lesions is of great 
importance to advancing the field. 
 
Clinical Course and treatment 
The first clinical description of CCM was reported by the German 
neuropathologist Hugo Kufs in 1928 (45). Overall, CCM disease can be divided into 
two categories: familial and sporadic. The field is currently divided as to the 
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proportion of familial versus sporadic cases. Historically, 20% of cases were thought 
to be familial and 80% sporadic, but estimates vary because of the modest sample 
size in these clinical studies (9). However, recent genetic work on sporadic patients 
possessing multiple lesions has shown that the majority of these cases were in fact 
familial (2). In both cases bi-allelic loss of ccm1, -2, or -3 occurs in endothelial cells, 
but familial patients exhibit higher lesion burden, with one study showing over 50% 
of familial patients having multiple lesions, whereas sporadic cases displayed 
multiple lesions in approximately 12% of cases (4, 46). Symptoms resulting from 
CCMs are similar between familial and sporadic forms, but familial patients generally 
present between infancy and thirty years of age, whereas sporadic patients 
generally present between forty and sixty years of age (9, 47). While CCM lesions 
can occur in many locations throughout the body, clinical manifestations are most 
common with CNS involvement. CCMs can cause a substantial variety of symptoms, 
including neurological deficits (e.g. dysphagia, hemiparesis, ataxia), epilepsy, and 
hemorrhagic stroke (48). 
Despite the genetic advances in understanding CCM and the commercial 
availability of CCM gene sequencing, MRI remains the gold standard for diagnosis, 
as well as differentiating familial from sporadic CCM (49, 50). Blood flow through 
CCMs is very low; unlike in related vascular malformations such as AVM, CCMs are 
very difficult to detect by angiography, and are therefore referred to as occult (51). 
CCM lesions appear on MRI as a “popcorn” pattern and often display a dark 
hemosiderin ring at the periphery of the lesion (51, 52). Yearly serial MRI is used to 
monitor lesion evolution in patients and guide clinical decisions about the need for 
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treatment (51). 
The standard of care for CCM disease is observation until symptoms 
necessitate intervention. The only medically treatable CCM symptoms are epilepsy 
and headache/migraine. However, anti-epileptics are ineffective for seizure control in 
half of CCM cases, and the headaches are only controllable through high dose 
narcotics; treatment regimens that have numerous side effects (53, 54). Intractable 
epilepsy, recurrent hemorrhage, and progressive neurological deficits are the 
primary indications for surgical resection of accessible lesions (39). 
Unfortunately, significant subsets of CCM lesions are considered surgically 
inaccessible, and these often have poorer natural histories than surgically accessible 
lesions. Generally, lesions are considered surgically inaccessible if surrounded by 
eloquent tissue such as the brainstem, spinal cord, or thalamus. Surgically 
inaccessible lesions are usually observed unless symptoms become overwhelming. 
Stereotactic radiosurgery has been touted as an alternative to traditional 
microsurgery for lesion removal, but high complication rates remain (55). While CCM 
outcome data is limited, one retrospective study of 95 patients found that 
radiosurgery was associated with a drop in annualized hemorrhage rate from 17 to 5 
percent after 2 years. However, at the 5 year follow-up 16 percent of patients 
displayed permanent neurological deficit and there was a 3 percent mortality rate, 
likely from radiation-induced injury (56). As neurosurgical interventions continue to 
advance, particularly in the fields of minimally invasive surgery and microsurgery, 
complications from routine CCM interventions can be expected to decline. However, 
neurosurgery and radiation will always cause complications to some extent, and as 
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previously noted, invasive intervention has been linked in some cases with lesion 
proliferation. Most importantly, lesions located in the brainstem or other eloquent 
areas will continue to present serious challenges for surgical therapy. Clearly, a 
better understanding of the CCM signaling network must be achieved, with the 
ultimate goal of producing a non-invasive pharmacological treatment for CCM 
disease. 
 
The CCM proteins: structure, function, and signaling 
 
CCM1 
CCM1, also known as Krit1 (Krev interaction trapped protein 1) is a 16 exon, 
736 amino acid protein that contains one band four point one ezrin/radixin/moesin 
(FERM) domain, three ankyrin repeat domains, and one Nucleoside Diphosphate 
linked to X (Nudix) domain (Fig. 1.2A) (57, 58). CCM1 was first identified in a yeast 
two-hybrid screen for binding partners of the small GTPase Rap1, and subsequently 
mapped to the Krit1 locus (57, 59, 60). CCM1, like CCM2 and -3, is a scaffold 
protein lacking any known catalytic domains. A crystal structure of the interaction 
between the FERM domain and the C-terminus of the orphan membrane receptor 
Heart of Glass (HEG1) has been solved, but CCM1 has not been crystalized alone 
(61). 
Multiple protein-protein interactions have been elucidated for CCM1. The 
FERM domain is composed of three subdomains, termed F1, F2, and F3, arranged 
in a cloverleaf shape (62). The F3 subdomain possesses a PTB-like sequence, 
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which interacts with an NPXY motif in the central region of CCM1 in a head-to-tail 
interaction, serving to maintain CCM1 in a closed conformation (63). This interaction 
is thought to regulate CCM1 activity by controlling access to the F2 and F3 FERM 
subdomains, which mediate binding with the small GTPase Rap1 (63). The CCM1-
Rap1 interaction is of great interest because Rap1 is a master regulator of vascular 
integrity and tight junction formation (64). 
CCM1 possesses an N-terminal NPXY motif, which interacts with the PTB 
domain of Integrin cytoplasmic domain-associated protein 1 (ICAP-1) (65, 66). ICAP-
1 is a negative regulator of β1-integrin activity because it competes with Talin, an 
integrin-cytoskeleton linking protein, for integrin binding (67). Structural work in 2013 
by Lui et al. demonstrated that indeed CCM1 functions as a molecular switch for β1-
integrin activation by regulating Talin-ICAP-1 association (32). Lui et al. also 
discovered the presence of a previously undescribed Nudix domain in a region 
formerly described as unstructured, although the functional significance remains 
unclear. Finally, while there are three ankyrin repeats present between the NPXY 
motifs and the FERM domain, no CCM1 ankyrin-mediated protein interactions have 
been found to date. However, ankyrin repeats commonly mediate protein-protein 
interactions, so it would not be surprising if their function is elucidated in CCM1 in 
the future (68). 
CCM1 binds the PTB domain of CCM2 through one of its NPXY motifs. 
Significantly, this binding is abrogated by a missense mutation at F217 in CCM2; 
thought to have the same effect as the known familial CCM2 mutation L198R, since 
both occur in the critical PTB domain (23, 69). CCM1 does not bind CCM3, although 
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the three CCM proteins exist in a ternary complex, with CCM1 and -3 bound to 
CCM2. CCM2 binding appears to regulate the subcellular localization of CCM1. 
Hilder et al. showed that CCM1 and -2 are primarily cytosplasmic when the wild type 
proteins are co-expressed, but that F217 mutation in CCM2 led to nuclear 
localization of CCM1 (42). Furthermore, CCM1 localizes to the nucleus in the 
absence of CCM2, and CCM2 does not enter the nucleus without the presence of 
functional CCM1 (15). The biological function of CCM1’s nuclear translocation is 
currently unknown. No evidence has been found that CCM1 directly regulates 
transcription. However, given that loss of CCM1 is associated with increased activity 
of the small GTPases RhoA and Rap1, it is possible that CCM1 may be affecting 
transcription through downstream regulation of transcription factors. Glading et al. 
demonstrated that loss of CCM1 led to accumulation of beta-catenin in the nucleus 
and a subsequent increase in beta-catenin-dependent transcription (70). Overall, 
CCM1 is perhaps the best-characterized CCM protein and appears to be the most 
commonly mutated as well. More work remains to be done on the CCM1-Rap1 
interaction as its dysregulation likely plays a role in CCM pathophysiology. 
 
CCM2 
CCM2, also known as Malcavernin and Osmosensing Scaffold for MEKK3 
(OSM) is a 10 exon, 453 amino acid protein containing a single PTB domain and a 
recently discovered domain termed Harmonin Homology Domain (HHD) (Fig. 1.2B). 
CCM2 was first identified by Uhlik et al. in a yeast two-hybrid screen using mitogen-
activated protein kinase kinase kinase 3 (MEKK3) as bait while investigating cellular 
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responses to hyper-osmotic shock (71). Concurrently, CCM2 was identified as the 
second human gene mutated in CCM by sequencing positional candidate genes 
based on earlier genetic mapping (19, 72). Like CCM1, no full crystal structure of 
CCM2 exists. However, a study in 2013 by Fisher et al. was able to crystalize the C-
terminal domain (approximately 200 AA) of CCM2 to a resolution of 1.9 Ångstroms. 
The C-terminal domain of CCM2 is homologous to the N-terminal domain of 
Harmonin; an adaptor protein linking actin to membrane bound proteins (73). 
Mutations in Harmonin cause Usher Syndrome (OMIM 276900), a condition in which 
patients display sensory-neural deafness, visual impairment, and vestibular 
dysfunction (74-76). The biological role of the HHD domain is thus far unknown, but 
reinforces the important scaffold or adaptor role CCM2 plays in cytoskeletal 
regulation. 
In contrast to the HHD domain, more is known about the function of the 
CCM2 PTB domain, with the Johnson lab undertaking the most comprehensive 
study of its role in 2007. Hilder et al. generated a point mutation (F217A) within the 
PTB domain, allowing for the definition of PTB-dependent binding partners for 
CCM2. The mutation was correctly predicted to disrupt CCM1-CCM2 binding, based 
on the finding of a similar mutation in patients abrogating the CCM1-CCM2 
interaction (23, 69). CCM3 bound full length, but not PTB-mutant CCM2, and CCM1 
and -3 were simultaneously isolated in a pulldown assay for CCM2 (69). This data 
indicated that a functional PTB domain is necessary for CCM1 and -3 interaction 
with CCM2, and that CCM1 and -3 bind CCM2 at distinct sites in the PTB domain. 
Perhaps most significantly, it also indicated that CCM1, -2, and -3 form a ternary 
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complex in the cell (69). 
Interestingly, recent work has discovered a CCM2 paralog, CCM2-like 
(CCM2L) that is expressed in endothelial cells during periods of cardiovascular 
development. CCM2L competitively inhibits CCM2 binding to CCM1 (but not CCM3), 
resulting in decreased angiogenesis in vitro and in vivo (77). The authors propose 
CCM2L as a molecular mechanism for coordinating vessel stability and growth in 
both development and postnatal vessel growth. The important role of CCM2L in 
endothelial cells, along with the mechanism of regulation suggests that the CCM 
signaling pathway is more important in development and vessel homeostasis than 
previously suspected.  
Finally, and perhaps most significant, is the work done by Crose et al. 
characterizing the molecular interaction between CCM2 and the E3 ubiquitin ligase 
SMURF1 (SMAD ubiquitin regulatory factor 1). Using mouse brain microvascular 
cells, it was demonstrated that the PTB domain of CCM2 interacts with the 
Homologous to the E6-AP Carboxyl Terminus (HECT) domain of SMURF1 and 
serves to localize it to the membrane where it targets the small GTPase RhoA for 
degradation (78). This is highly significant because we hypothesize that 
dysregulation of E3 ligases is a molecular mechanism of CCM pathogenesis. This 
hypothesis will be discussed in further detail in subsequent sections. Overall, much 
has been discovered about CCM2 since it was cloned by Uhlik et al. in 2003. CCM2 
is thought to be the common linker in the CCM ternary complex, with both CCM1 
and -3 binding to it, and it would be unsurprising if diverse molecular interactions 
featuring its PTB domain were described in the future. 
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CCM3 
CCM3, also known as PDCD10 (Programmed Cell Death 10), is a seven 
exon, 212 amino acid protein with a dimerization domain and Focal Adhesion 
Targeting-homology (FAT) domain (Fig. 1.2C). CCM3 was the most recent gene 
linked to CCM, and is also the smallest at 25 kilodaltons. CCM3 was identified by 
high-density microsatellite genotyping in a set of familial CCM patients testing 
negative for CCM1 or -2 mutation (21). Initial in vitro work suggested that CCM3 
performed anti-apoptotic functions. For example, one study showed that introduction 
of recombinant CCM3 decreased natural cell death in fibroblast cell lines treated 
with apoptosis inducers, including TNF-α, staurosporin, and cyclohexamide (79). 
CCM3 is the only CCM protein for which a high-resolution crystal structure has been 
solved. Li et al. showed that CCM3 binds CCM2 via the FAT homology domain and 
that mutation of a conserved FAK-like hydrophobic pocket abrogates CCM2-CCM3 
interaction (80). It was also demonstrated that the FAT homology domain interacts 
with paxillin, and the two proteins co-localize in several cell types (62). Furthermore, 
truncating mutations of the CCM3 FAT domain are seen in familial CCM disease, 
suggesting that the full presence of this domain is essential to the function of the 
CCM proteins and complex. CCM3 has an N-terminus dimerization domain, and has 
been shown to exist as a homodimer both in vitro and in vivo (80, 81). 
CCM3 participates in diverse signaling pathways in endothelial cells, and 
several molecular mechanisms have been proposed to explain how CCM3 mutation 
results in the disease phenotype. One pathway of interest is between CCM3 and the 
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Germinal Center Kinase III sub-family (GCKIII) of the Sterile 20 protein kinase 
family, including mammalian Sterile 20-like protein kinase 4, and Serine/Threonine-
protein kinase 24 and 25 (STK24 and STK25). Work in zebrafish showed that both 
STK knockdown and low-level STK and CCM3 knockdown resulted in a CCM 
cardiovascular phenotype (82). Furthermore, depletion of STK25 in Human Umbical 
Vein Endothelial Cells (HUVEC) leads to increased barrier permeability; a hallmark 
of CCM protein loss. The molecular interaction was later defined when it was 
demonstrated that the N-terminus of CCM3 heterodimerizes with the GCKIII proteins 
in a mechanism similar to CCM3 homodimerization (83). Importantly, it was shown 
that the STKs directly activate the cytoskeletal scaffold protein Moesin, and that a 
loss of active Moesin results in increased RhoA activity (82). While further work is 
needed to clarify the role of the GCKIII kinases in CCM pathogenesis, it is clear that 
the STKs are important downstream effectors for CCM3. 
Another molecular interaction of significance has been demonstrated between 
CCM3 and Vascular Endothelial Growth Factor 2 (VEGFR2). VEGFR2 expression is 
restricted to endothelial cells (both vascular and lymphatic) and is a master regulator 
of vascular endothelial function, such as proliferation, migration, survival, 
permeability, vasculogenesis, and angiogenesis (84). He et al. generated a CCM3 
conditional knockout mouse that demonstrated defects in VEGFR2 signaling, 
including decreased VEGFR abundance and decreased phosphorylation of 
downstream proteins Akt and Phospholipase C gamma (34). Most interestingly, this 
work showed that CCM3 is recruited to and stabilizes VEGFR2 in the presence of 
VEGF stimulation, and this interaction is abrogated in premature truncation 
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mutations affecting the C-terminal of CCM3 seen in familial CCM3 patients. The 
authors concluded that CCM3 regulates vascular development by modulating 
VEGFR2 signaling. The CCM3-VEGFR2 interaction is compelling because of 
VEGFR2’s importance in vascular regulation and the fact that clinically relevant 
CCM3 C-terminal mutants lead to destabilization of VEGFR2. However, this work 
has not been replicated thus far, and while previous groups have looked at VEGF 
signaling in the context of CCM mutation, nothing of significance was found. CCM3 
remains the most enigmatic CCM protein, with a rapidly increasing literature on 
signaling, albeit with some disagreement between investigators on its role in the 
CCM pathway. Given the wealth of structural knowledge that has been elucidated 
recently, knowledge of CCM3 should continue to expand rapidly in the near future.  
 
The CCM regulatory network 
Virtually everything known about the CCM signaling network has been 
discovered within the last 10 years. While much more is known now than a decade 
ago, defining the molecular mechanism of CCM disease remains elusive. 
Structurally, the proteins are quite different, only unified by their lack of recognized 
catalytic domains. While recent work has defined separate molecular pathways for 
CCM1, -2, and -3, the significance to CCM disease remains unclear. Yet clinically 
and pathophysiologically, mutation of the 3 CCM proteins is indistinguishable. CCM 
mouse models exhibit similar phenotypes, and all are embryonic lethal at E9.5 due 
to defects in the dorsal aorta and branchial arches; classic defects in angiogenesis 
(31, 34, 85). Even in vitro phenotype studies fail to distinguish differences in loss of 
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the CCM proteins, with loss of CCM1, -2, and -3 resulting in similar increases in 
stress fibers, decreased capillary-like tube formation, and increased endothelial 
monolayer permeability. Hilder et al. showed that the CCM proteins form a ternary 
structure, suggesting that the full CCM complex may be required for normal 
endothelial cell function. While this hypothesis is difficult to prove because of the 
lack of suitable fluorescent CCM antibodies, it is clear that the CCM proteins 
regulate one important common pathway in endothelial cells: RhoA and therefore 
Rho kinase (ROCK) activity.  
 
RhoA and Rho kinase signaling 
 The similar biochemical and phenotypic abnormalities seen with loss of any of 
the 3 CCM proteins suggests that they coordinately regulate a common mechanism 
for maintaining vascular integrity. Recent work in our lab and by others has 
implicated dysregulation of RhoA as a mechanism for loss of vascular integrity in 
CCM (32, 78, 86). RhoA is a 21 kilodalton small GTPase and first-identified member 
of the Rho family, which is in turn a subfamily within the Ras superfamily (87). 
Members of the Rho family are key regulators of the actin cytoskeleton. RhoA is 
activated by diverse signals, including G-protein coupled receptors, receptor tyrosine 
kinases, and integrins, and is both activated by ligands and by mechanosensory 
mechanisms such as shear stress (88, 89). Like all small GTPases, RhoA is active 
when bound to GTP and inactive when bound to GDP, and activation state is 
regulated by Guanine Nucleotide Exchange Factors (GEFs), GTPase activating 
proteins (GAPs), and Guanine Nucleotide Dissociation Inhibitors (GDI) (90, 91). The 
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primary function ascribed to RhoA is regulation of actin and microtubule cytoskeletal 
dynamics, an action that occurs primarily through regulation of ROCK (90). 
Importantly, normal RhoA activity is essential for proper endothelial cell function. 
RhoA activity is essential to the dynamic regulation of permeability required of 
endothelial and smooth muscle cells, along with facilitating diapedesis of leukocytes. 
Furthermore, a number of vascular defects are associated with aberrant RhoA 
activity or loss. Expression of constitutively active RhoA decreases formation of 
capillary-like tubes on Matrigel, and GEMMs with knocked out RhoA or RhoA 
regulatory proteins exhibit embryonic lethality due to failed vascular patterning and 
defective sprouting angiogenesis, supporting the crucial role of RhoA in 
angiogenesis (92). Overall, RhoA has been defined as a master regulator of the 
actin cytoskeleton and clearly plays a critical role in endothelial cell biology. 
Importantly, and perhaps unsurprisingly given its importance in angiogenesis, 
RhoA has been implicated in CCM signaling and CCM disease. In an experiment 
that has shaped the course of CCM research, Crose et al. showed that CCM2 binds 
the E3 ubiquitin ligase Smurf1 and localizes it to the membrane, where it degrades 
RhoA (78). Further studies showed that loss of CCM1, -2, or -3 in endothelial cells 
results in significantly elevated RhoA levels (86). Not only was total RhoA increased, 
but it was persistently hyperactivated in cells lacking the CCM proteins. RhoA is an 
important upstream regulator of actin, affecting cytoskeletal dynamics through 
activation/phosphorylation of its effector ROCK (93). ROCK is a 160 kilodalton 
member of the AGC protein kinase family, and significantly, has been the focus of a 
substantial effort to achieve small molecule inhibition because ROCK 
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hyperactivation has been implicated in both hypertension and cancer metastasis (94, 
95). ROCK affects actin through parallel pathways involving Myosin Light Chain 
Phosphatase (MLCP) and LIM kinase (LIMK), both important cytoskeletal regulators 
through their effectors Myosin Light Chain 2 (MLC2) and cofilin, respectively (96-98). 
Phosphorylation of MLC2 and cofilin favors actin assembly and stress fiber formation 
(99, 100). Phospho-MLC2 stays bound to actin, encouraging stress fiber formation 
and contraction (101). MLCP is a widely expressed phosphatase that 
dephosphorylates myosin light chain (102). MLCP opposes the action of myosin light 
chain kinase (MLCK), but it appears that ROCK-mediated inhibition of MLCP is more 
physiologically important for regulating MLC2 phosphorylation than MLCK activity 
(103). Phosphorylation of MLC2 favors stress fiber formation and cell contraction, 
phenotypes seen in CCM knockdown cells in vitro. While ROCK is a direct regulator 
of actin organization in endothelial cells, it is also an important indirect cytoskeletal 
effector through regulation of LIM kinase (LIMK).  
 
LIM kinase and cofilin 
LIMKs are widely expressed serine-protein kinases consisting of two highly 
homologous isoforms, LIMK1 and LIMK2 (104-107). LIMKs possess 2 LIM domains 
in addition to a protein kinase domain (108, 109). LIM domains are tandem zinc 
finger structures that function as modular protein binding interfaces (108, 109). 
There is emerging evidence that the two forms may have distinct yet overlapping 
functions, but because they function similarly as effectors for RhoA-ROCK signaling, 
they will be referred to by the generic term “LIMK”, unless specific differences have 
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been established between the two (110). Interestingly, loss of function in LIMK is 
thought to cause Williams syndrome, a neurodevelopmental disorder associated 
with a number of vascular defects (111). 
LIMKs are important regulators of actin dynamics through cofilin, an actin 
depolymerizing factor (112, 113). When phosphorylated by LIMK, cofilin’s actions on 
acting severing and monomer dissociation are decreased. ROCK phosphorylates 
LIMK at threonine 505 or 508, which in turn phosphorylates cofilin at serine 3 (114). 
Unphosphorylated cofilin severs actin filaments with uncapped ends, leading to an 
increase in the number of free filament ends (115, 116). Cofilin also enhances the 
rate of monomer dissociation from the pointed ends of actin (117, 118). Together, 
these actions lead to increased actin turnover and a more dynamic cytoskeleton. 
However, when phosphorylated by LIMK, cofilin is unable to bind and depolymerize 
actin (119). This leads to an increase in F-actin, a phenotype similar to that seen in 
endothelial cells lacking CCM proteins (120-122). 
Previous work has characterized LIMK as being regulated by RhoA-ROCK in 
endothelial cells, and defined a role in maintaining vascular integrity in other systems 
(123, 124). In human endothelial cells stimulated with thrombin, ROCK 
phosphorylates LIMK, leading to phosphorylation and inactivation of the actin-
depolymerizing factor cofilin and promoting assembly of actin and stress fibers (99). 
LIMK and cofilin phosphorylation is decreased and stress fiber quantity normalized 
upon treatment with the ROCK inhibitor Y-27632, demonstrating that RhoA-ROCK-
LIMK signaling plays an important role in regulating endothelial cell actin dynamics 
(99). Additionally, recent work in several disease models confirmed LIMK as an 
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important regulator of vascular integrity in vivo. In one study, endotoxin stimulation 
led to increased RhoA and LIMK activation, followed by increased endothelial 
permeability and subsequent mortality in wild type mice. LIMK-/- mice showed lower 
permeability and mortality in response to endotoxin treatment (124). In humans, 
several LIMK haplotypes have been linked to the rupture of intracerebral aneurisms 
in the Japanese population (125). Furthermore, LIMK has been shown to play an 
important role in modulating invasion and migration, characteristics important to 
endothelial cells for maintaining endothelial barriers (126-128). 
LIMK hyperactivation resulting from loss of the CCM proteins raises the 
possibility of chemical inhibition of LIMK as a therapeutic target for CCM disease. 
The LIMK-cofilin pathway is further downstream of RhoA and ROCK, and 
furthermore cofilin is the only known target for LIMK (111). Unlike ROCK, no 
commercially available inhibitors of LIMK exist. However, like ROCK, LIMK 
hyperactivation has been implicated in a number of important diseases such as 
cancer. Therefore it seems likely that LIMK inhibitors will be brought to market in the 
near future, and if so they should definitely be tested in the context of CCM. 
However, it is currently difficult to test pre-clinical efficacy of pharmacological 
inhibitors because of a lack of availability of human endothelial cells with CCM gene 
mutations. 
 
Endothelial precursor-derived endothelial cells 
Rationale for development of a novel human primary cell system 
 One of the challenges in CCM research is the lack of an unquestionably 
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biologically relevant human cell system to work with. Availability of human lesions is 
limited, although the patient advocacy group The Angioma Alliance maintains a 
growing bio-bank of frozen lesions. Even though the number of CCM mouse models 
has increased greatly in the last 5 years, problems remain. Several of the GEMMs 
are ccm heterozygotes crossed on a mismatch repair background, which does result 
in reliable lesion generation but may not be a truly physiologically relevant model. 
Furthermore, while mouse models are unquestionably useful for advancing the CCM 
field, human and mouse pathophysiology can be substantially different at times, as 
evidenced by the numerous examples in other fields of pharmacological therapies in 
mice that were ineffective in humans (129). Similarly, while important work, 
especially in vascular development, has been done on CCM orthologues in 
zebrafish, biological relevance to the human disease is questionable. For example, 
much work has been done to characterize the interaction between the CCM1 and -2 
orthologues santa and valentine and the orphan receptor HEG1 in zebrafish, with 
investigators showing that loss of HEG1 phenocopies loss of the CCM proteins, and 
HEG1 couples to CCM1 to regulate endothelial cell junctions (33, 130). However, no 
HEG1 homologue exists in humans, and no CCM3 orthologue exists in Danio rerio. 
Current in vitro work relies mainly on HUVECs, along with other mouse and human 
cell lines such as human microvascular endothelial cells and mouse embryonic 
endothelial cells (MEECs). Techniques such as RNAi and fluorescent protein 
tagging in cells have helped greatly in elucidating the CCM signaling network, but in 
the end knockdown or knockout of the CCM proteins may not replicate the biological 
effect of the CCM mutations seen in human patients. Therefore, defining and 
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optimizing a method of obtaining endothelial cells from CCM patients would be of 
great benefit to the field. One way of achieving this goal is by deriving endothelial 
cells from CCM patients, and this can be accomplished by isolating endothelial 
progenitor cells (EPCs) from peripheral blood. 
 
Endothelial progenitor cells and endothelial progenitor-derived endothelial cells 
 EPCs were first described by Asahara et al. as a CD34 positive subset of 
peripheral blood mononucleocytes (PBMC) that expressed VEGFR2, CD31, and 
endothelial constitutively nitric oxide synthetase, all markers specific to endothelial 
cells, in addition to the stemness markers CD34 and AC133 (131, 132). Some EPCs 
circulate, but the majority reside in the bone marrow, and they contribute significantly 
to the repair and formation of new blood vessels in adults (133). Further work 
showed that EPCs can differentiate into vascular endothelium in response to both 
growth factors and vascular injury, leading to the concept that vasculogenesis and 
angiogenesis may occur simultaneously in postnatal life (134).  
 Importantly, EPCs will differentiate into endothelial cells when cultured on 
fibronectin for 7 days in media with the appropriate mix of endothelial cytokines. We 
term these outgrowth cells endothelial progenitor-derived endothelial cells (EP-ECs). 
EP-ECs have great potential in CCM research because they are endothelial cells 
that can be isolated from peripheral blood of CCM patients. These endothelial cells 
would be heterozygous and therefore would better reflect the biology of CCM 
mutation because mutant protein would be expressed, rather than knocked down or 
-out as can be achieved with RNAi. Sh or siRNA could be designed to knock down 
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expression of either the remaining wild type allele or the mutant. In fact, EP-ECs 
have recently been used to investigate the mechanism of corticosteroid therapy in 
infantile hemangioma (OMIM 602089), a vascular disorder related to CCM. Using 
EP-ECs derived from hemangioma patients with confirmed genetic mutations, 
Greenberger et al. demonstrated that the corticosteroid dexamethasone causes 
lesion regression by inhibiting the proliferation potential of EP-ECs (135). Patient 
derived EP-ECs could be a powerful new system for studying endothelial biology 
and vascular disease. EP-ECs could even be combined with induced pluripotent 
stem cell techniques to create a library of human CCM gene mutations. Certainly, 
EP-ECs would be an ideal system for studying drug response and pharmacological 
therapy for CCM. However, the use of EP-ECs is not without caveats. Our 
experience has been that they cannot always be successfully isolated from donors, 
and investigators report differing rates of success in achieving EP-EC outgrowth. 
While not published, discussion with EP-EC experts and our own personal 
experience suggests that age and sex of the donor may play a substantial role in the 
amount of circulating EPCs and their proliferative potential. Certainly, further 
characterization is warranted, given the potential of EP-ECs in CCM and 
cardiovascular investigation in general. 
 
The future of pharmacological treatments for CCM Disease 
 CCM is a difficult disease to treat. The standard of care is observation with 
surveillance by serial MRI. Symptoms secondary to CCM, such as migraines and 
epilepsy, are managed with appropriate medications such as Triptans and 
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anticonvulsants. When symptoms become intolerable, the only options are surgery 
or radio-ablation. However, these treatments are associated with a number of 
serious complications, and there is some evidence that invasive intervention can 
trigger further lesion evolution. Furthermore, some CCM lesions, including the ones 
most likely to exhibit severe symptoms, are located in surgically inaccessible areas 
such as the brainstem or pons. Therefore, discovery of a pharmacological treatment 
for CCM is of paramount importance. 
 The increase in the understanding of CCM signaling pathways in the last 
decade has made the discovery or synthesis of a CCM therapeutic increasingly 
possible. Specifically, attention is focused on two therapeutic avenues: small 
molecule ROCK inhibitors, or off-label use of currently Food and Drug Administration 
(FDA) approved drugs. 
 
Statins  
The advantages of using drugs already approved by the FDA are that basic 
safety and dosing information in humans is known, and lengthy and expensive pre-
clinical workup is not required. The most promising class of FDA approved drugs 
proposed to treat CCM are statins, in particular Simvastatin, because of their 
potential as RhoA activity inhibitors. Statins have been used to treat 
hypercholesterolemia/dyslipidemia since 1987, and are widely regarded as effective 
and safe (136). Statins lower cholesterol by inhibiting 3-hydroxy-3-methyl-glutaryl-
CoA reductase (HMG-CoA Reductase), an enzyme which catalyzes the conversion 
of HMG-CoA into mevalonate and is the rate-limiting step in cholesterol synthesis 
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(136). However, statins are also associated with a number of beneficial pleotropic 
effects, including improved endothelial relaxation, reduced arteriosclerosis 
progression, improved hypertension control, and increased cardiac ejection fraction 
(137). It is thought that most of the pleotropic effects from statin treatment come 
from indirect inhibition of small GTPases such as RhoA and Ras (138). Mevalonate 
can be converted into the isoprenoid residues farnesylpyrophosphate and 
geranylgeranylpyrosphosphate, which can be covalently attached to intracellular 
proteins through prenylation (139). Small GTPases are particularly dependent on 
prenylation for localization and activity, and it has been demonstrated that statins 
can inhibit angiogenesis by inhibiting RhoA geranylgeranylation and therefore 
preventing proper RhoA localization (140). This finding is important for the CCM field 
given that loss of the CCM proteins results in RhoA hyperactivation. Given the well-
documented cardiovascular protective effects of statins, and their good safety 
profile, statins have been discussed as a possible CCM treatment for several years. 
Significantly, in 2009 Whitehead et al. demonstrated that permeability barrier 
function could be rescued in heterozygous CCM2 mice with Simvastatin treatment 
(32). 
Excitingly, the first clinical trial using statins for CCM was initiated in January 
2013. Titled “Permeability MRI in Cerebral Cavernous Malformations Type 1 in New 
Mexico: Effects of Statins” (clinicaltrials.gov identifier NCT01764451), the study is 
recruiting patients with CCM1 mutations and will follow placebo and Simvastatin 
treatment with MRI to assess vascular competence of the blood brain barrier (141). 
While this study is just beginning and is only a Phase 0 trial, it is an encouraging 
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start for CCM patients. Another way to study statin effectiveness on CCM would be 
to conduct a retrospective cohort study of CCM patients taking statins. The feasibility 
would be limited by the number of overlapping hypercholesterolemia and CCM 
patients, and the availability and accessibility of medical records. However, given 
that approximately 1 in 200 of the general population has a CCM mutation, and 
approximately 1 in 4 Americans over 45 are thought to take statins regularly, it is 
possible that significant data could be gleaned from such a study (136).  
 
Rho kinase inhibitors 
  A second promising therapeutic strategy for treatment of CCM is small 
molecule inhibition of ROCK (Fig. 1.3). As discussed previously, loss of CCM1, -2, or 
-3 results in increased ROCK activity in cultured endothelial cells, mouse models, 
and human lesions (32, 78, 86, 142). Furthermore, both RNAi knockdown and 
chemical inhibition of ROCK have been demonstrated to rescue the CCM phenotype 
in vitro (86, 142). Most significantly, a recent study in a CCM mouse model 
demonstrated that dosing with a small molecule ROCK inhibitor reduced CCM lesion 
size and overall lesion burden (143). Previous mouse work had shown that ROCK 
inhibition rescued vascular leak in ccm1 and -2 heterozygous mice (142). In some 
ways, ROCK is a more attractive target than RhoA because it is more specific. 
RhoA, and lipid prenylation in general, are extremely important in most cells, 
whereas ROCK is a single arm of the RhoA pathway. Additionally, ROCK2 
expression is restricted to the brain and endothelial cells, providing perhaps an even 
more selective target (144). Perhaps more importantly, there is great interest in 
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development of small molecule inhibitors for ROCK by both the pharmaceutical 
industry and academia because of the applications to both cardiovascular disease 
and cancer. CCM patients may benefit from the applicability of ROCK inhibition to 
these diseases as increasingly potent and specific ROCK inhibitors are developed 
and brought to market. 
 Currently no ROCK inhibitors are approved for use in humans in the United 
States. However, one compound, Fasudil, has been used in Japan since 1995 to 
treat cerebral vasospasm, and is well tolerated in humans and mice (145). Cerebral 
vasospasm is an intense vasoconstriction in brain arteries that occurs following brain 
hemorrhage, most commonly after sub-arachnoid hemorrhage. In the United States, 
calcium channel blockers such as Nimodipine and Nicardipine are used instead of 
Fasudil (146). Studies have shown that Fasudil is effective in reducing vasospasm 
from 57 to 37% with subsequent reduced mortality and improved outcomes (147). 
Importantly, this data demonstrates safety and efficacy in humans, as well as the 
ability of Fasudil to cross the blood brain barrier and act on cerebral blood vessels.  
 
Defining the molecular mechanism of CCM disease 
Overall, great progress has been made in defining the structure and function 
of the three CCM proteins over the last decade. However, much remains to be 
discovered about the role of the CCM proteins both in normal biology and disease. 
The objective of this project is to define the CCM regulatory network, and 
therefore the molecular mechanism of CCM pathophysiology. The question 
remains: how does loss of these three proteins lead to indistinguishable clinical 
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outcomes, despite their heterogeneous functions in the cell. We propose that the 
CCM proteins regulate RhoA activity and that the common pathway of CCM 
disease is hyperactivation of the RhoA/ROCK signaling network (Fig. 1.4). The 
phenotypes of CCM knockdown endothelial cells, along with the cytoskeletal 
signaling dysregulation observed, are consistent with RhoA hyperactivity. We have 
demonstrated increases in total RhoA and RhoA activity through Western blotting, a 
RhoA biosensor, and active RhoA pulldowns. Furthermore, we have shown that the 
ROCK targets MLC2 and LIMK are hyperphosphorylated with loss of the CCM 
proteins, with deleterious consequences on the ability of the actin cytoskeleton to 
undergo the profound changes required of endothelial cells. Both 
hyperphosphorylation and phenotype defects are reversed by chemical inhibition of 
ROCK or knockdown of ROCK or LIMK, indicating the importance of RhoA-ROCK 
signaling to CCM. Yet the molecular mechanism whereby loss of the CCM proteins 
results in RhoA hyperactivation remains elusive.  
The similar increase in RhoA-ROCK activity observed with loss of CCM1, -2, 
and -3, along with the binding data indicating that the three proteins exist as a 
ternary complex in the cell, initially lead us to hypothesize that all three functioned on 
a common molecular pathway to regulate RhoA activation. Crose et al. 
demonstrated that CCM2’s PTB domain interacts with the HECT domain of 
SMURF1, and CCM2 acts to localize SMURF1 to the cell membrane to regulate 
localized degradation of RhoA (78). Recent work has lead to the understanding that 
ubiquitin-mediated proteosomal degradation plays an important role in spatio-
temporal control of RhoA signaling and protein abundance, and this along with 
 31 
Crose’s data lead us to hypothesize that CCM1 and -3 likely regulated RhoA activity 
through E3 ligases, either SMURF1 or -2 (148). However, CCM1 and -3 do not 
possess a PTB domain like CCM2, and we have been unable to show that they bind 
endogenous SMURF1 or -2. Therefore, we propose that the CCM proteins 
regulate RhoA activity through separate molecular pathways. We hypothesize 
that CCM2 regulates RhoA through spatio-temporal regulation of SMURF1, 
that CCM1 regulates subcellular localization of CCM2 and thus SMURF1 
degradation of RhoA, and CCM3 regulates RhoA through a currently unknown 
mechanism, although likely by influencing CCM2 through it’s interactions with 
the CCM complex.  
It is clear that the CCM proteins regulate a complex network of proteins in 
endothelial cells. A new technique pioneered by the Johnson lab, Multiplexed 
inhibitor beads coupled with mass spectrometry (MIB-MS) allows us to look in an 
unbiased way for the first time at the effects of loss of the CCM proteins on the entire 
kinome of the cell. MIB-MS has demonstrated that the CCM proteins, likely through 
regulation of small GTPase activity, affect a surprisingly high number of kinases, 
including several critical to angiogenesis and transcription, such as the angiopoetin 
receptor (TIE2) and Transforming growth factor beta-receptor (TGFβR). This windfall 
of data about the CCM regulatory network needs further investigation and 
interpretation, but demonstrates the critical role these proteins play in endothelial 
cells, and is encouraging for future rational design and testing of therapeutics for 
CCM disease. 
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Figure 1.1: Histopathology of a CCM lesion. Note loss of normal vascular 
architecture and replacement with dilated capillary-like structures and calcified or 
necrotic parenchyma. 
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Figure 1.2: Representation of the known structural features of the CCM proteins. 
Binding partners are listed underneath domains. Adapted from Richardson et al. 
(149). 
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Figure 1.3: Chemical representations of two structurally distinct commonly used Rho 
kinase inhibitors, Fasudil and Y-27632. 
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Figure 1.4: Representation of regulation of the RhoA-ROCK signaling pathway by 
the CCM proteins. (A) In the presence of all three CCM proteins, SMURF1 is 
localized to the plasma membrane where it serves to degrade RhoA, therefore 
regulating ROCK signaling and balancing cytoskeletal dynamics between 
breakdown and assembly. (B) With loss of CCM1, -2, or -3, degradation of RhoA is 
dysregulated and total and active RhoA increases, leading to an increase in 
downstream ROCK signaling. RhoA-ROCK-LIMK hyperactivation leads to increased 
actin stress fiber assembly through phosphorylation of MLC2, and increased F-actin 
through phosphorylation of cofilin. 
 
 
 
 
 
II. Materials and Methods 
 
Chapter III 
Establishment of knockdown cell lines 
Lentiviral gene-specific shRNAs in pLKO.1 were obtained from the UNC-CH 
Lenti-shRNA Core Facility. Infection was accomplished using Lipofectamine 2000 
(Invitrogen) and cells were selected for resistance with 4µg/mL puromycin. Stable 
knockdown was achieved and measured by real-time PCR with CCM specific 
primers. Experiments were conducted between 1 and 2 weeks after infection to 
ensure stable protein knockdown. Multiple shRNAs were used for the same protein 
to control for off target effects. 
 
RhoA biosensor 
RhoA biosensor studies were performed by Dr. Asya Borikova of the Johnson 
lab. The RhoA biosensor was a kind gift from Dr. Klaus Hahn of UNC pharmacology. 
A single chain eYFP-eCFP RhoA biosensor was encoded in an adenoviral vector, 
and expanded using the ViraPower Adenoviral Expression System (Invitrogen). 5.0 x 
10^4 MEECs were seeded on fibronectin coated coverslips, and infected with the 
biosensor after 24 hours. Cell imaging was performed 24 hours later and images 
were processed as previously described by Pertz et al. (150). 
 
 37 
Tube formation assay and live cell imaging 
7.0 x10^4 cells were incubated for 15 hours on Matrigel (BD Biosciences) and 
stained with rhodamine-phalloidin as previously described (78). Imaging was 
performed on either a Pathway (BD Biosciences) or Cellomics ArrayScan (Thermo 
Scientific). For live cell imaging, 6 fields of cells were imaged via transmitted light 
microscopy every 10 minutes for 15 hours. Cellomics Arrayscan software was used 
to quantitate mean tube area. 
 
Statistical significance  
Where indicated, statistical significance was calculated using the two-tailed 
Student’s t-test. Data represented the mean of at least 2 experiments.  
 
Invasion assays 
 5.0x104 cells in 0.05% FBS/DMEM were seeded in the top chamber of a 
Biocoat Matrigel invasion chamber (BD Biosciences) with 1.5% FBS/DMEM in the 
bottom chamber. At 8 hours cells were fixed, permeabilized and stained with 
rhodamine-phalloidin. For each membrane, five fields of cells were counted. For 
assays with Y-27632, cells were treated with 10µM Y-27632 (Calbiochem) for 5 
hours prior to and during invasion assays. 
 
Image analysis 
 Densiometry for Western blots, and image analysis for RhoA biosensor, 
invasion and tube formation were performed with ImageJ (NIH). Dr. Noah Sciaky of 
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the Johnson lab performed image analysis for the tube formation assays. 
 
Western blotting 
100 µg of protein were separated by Western blot and blotted with anti-RhoA 
(Santa Cruz, 26C4) or anti-phospho-MLC2 (Cell Signaling, Ser19) antibody or 
mouse monoclonal anti-CCM2 antibody (Johnson lab, UNC 48.8.5). 
 
Chapter IV 
Mutation sequence analysis of human samples 
Lesions were acquired through the kind of help of Dr. Amy Akers and the 
Angioma Alliance’s CCM DNA and Tissue Bank (www.angiomaalliance.org). Lesions 
were resected from clinically and radiographically confirmed familial CCM patients. 
The sequence of CCM gene mutations were determined by screening peripheral 
blood mononucleocyte DNA with a panel of CCM PCR probes. This is the standard 
method for genetic diagnosis of CCM in patients.  
 
Immunohistochemistry 
Immunohistochemistry was performed with the assistance of the Dr. Nana 
Feinberg and the UNC Translational Pathology Laboratory. Tissue slide preparation: 
Cell pellets were resuspended at 50°C in 2% low melting agarose (#BP-165-25, 
Fisher Scientific) in PBS buffer and transferred to plastic molds. Pellets were allowed 
to harden at 4°C and then pushed out from the mold to the tissue processing 
cassettes. Cell clots were processed according to standard procedures for large 
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tissues. 
Chromogenic detection: immunohistochemistry was performed in a Bond 
Autostainer (Leica Microsystems). Antigen retrieval for both phospho-cofilin and 
CD31 antibodies was performed for 30 min at 100 ºC in Bond-Epitope Retrieval 
solution. Slides were incubated in anti-phospho-cofilin or anti-CD31 primary 
antibodies for 1hour. Rabbit monoclonal phospho-cofilin, Ser3, 77G2, (Cell Signaling 
Technology) was used at 1:300 and mouse monoclonal CD31-1A10-CE-S (Leica 
Microsystems) at 1:200. Antibody detection was performed using the Bond Polymer 
Refined Detection System. 
Fluorescence detection: Tissue slides were first incubated with anti-CD31 
antibody (1:200) to create the endothelial cell mask. CD31 was detected by HRP 
linked Bond Polymer. After CD31 staining, anti-phospho-cofilin antibody (1:300) was 
applied. Goat anti-mouse-HRP (Envision+) was used as a secondary antibody and 
Cy5-tyramide (PerkinElmer) as a fluorescent tag. The stained slides were mounted 
with ProLong Gold antifade reagent (Molecular Probes) containing 4,6-diamidino-2-
phenylindole (DAPI) to define nuclei. 
Aperio FL/AQUA image analysis: Aperio FL (Aperio) with integrated HistoRx 
AQUA technology (HistoRx) was used to scan slides at 20x through DAPI, CY3 and 
CY5 channels. Scanned images were analyzed through spectrum using the AQUA 
traditional algorithm according to AQUAnalysis™ Aperio Edition (Rev. 1.0, 
CDN0044, HistoRx). 
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Cell Culture and shRNA 
bEND.3 cells were purchased from ATCC. Lentiviral gene-specific shRNAs in 
a pLKO.1 system were generated by the University of North Carolina-Chapel Hill 
Lenti-shRNA Core Facility. Infection was performed according to the RNAi 
consortium protocol. bEND.3 cells were cultured in 10% FBS/DMEM, Mouse 
Embryonic Endothelial Cells (MEEC) in 3% FBS/DMEM, and Human Umbilical Vein 
Endothelial Cells (HUVEC) in EGM2 media (Lonza). 4µg/mL puromycin was used to 
maintain shRNA selection. HUVECs were used up to passage 4. 
 
Immunofluorescence 
Glass coverslips were coated for 1 hour at 37 ºC with a solution of 1:50 
Growth Factor Reduced Matrigel (BD Biosciences) in PBS. 5.0x10^3 bEND.3 cells 
were seeded in a 6-well plate containing Matrigel-coated glass coverslips and 
incubated for 24 hours. Cells were then fixed in 3% Paraformaldehyde, 
permeabilized, and stained with Alexafluor 488-Phalloidin, anti-phospho-cofilin with 
an Alexafluor 555 secondary, and Hoechst dye. Images were taken from 5 
representative fields with a 40x oil objective (Zeiss Axiovert 200). For quantitation, 
fluorescent images were collected using a Nikon 80i Research Upright Microscope 
(Nikon, Tokyo, Japan) equipped with Surveyor Software with TurboScan (Objective 
Imaging, Kansasville, WI). Image montages were collected using a Qimaging 
Retiga-EXi camera (Qimaging, Surrey, BC, Canada). Separate images were 
collected for the nucleus (Hoechst), actin (green) and target channel (cofilin; red 
channel) using a 10x objective. The area per cell was measured by cropping 
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images, creating binary masks for each cell by manually defining the cell boundaries 
using ImageJ (NIH) and then automatically extracting geometric features using 
Cellprofiler software (Broad Institute of Harvard and MIT, Cambridge, MA). 
 
Functional assays 
Tube formation: 7.5 × 10^4 cells were incubated for 15 hours on Matrigel (BD 
Biosciences), fixed, permeabilized, and stained with rhodamine-phalloidin and 
Hoechst. Imaging was performed on a Cellomics ArrayScan (Thermo Scientific) or a 
Pathway (BD Biosciences). Mean tube area was quantitated with Cellomics 
Arrayscan software. 
 
Matrigel invasion: 4.0x10^3 MEECs were plated in serum-free media on a 
Matrigel-coated invasion chamber (BD Biosciences) with 1.5% FBS containing 
media and incubated for 8 hours. Wells were fixed, permeabilized, and stained with 
rhodamine phalloidin and Hoechst. Images were taken from 5 representative fields 
per sample on a confocal microscope (Zeiss) and quantitation was achieved by 
counting nuclei on an ImageJ macro. 
 
Western blotting 
50µg of total protein cell lysates were separated on an SDS-PAGE gel. 
Membranes were probed with anti-RhoA (Santa Cruz), anti-LIMK1, anti-phospho-
LIMK1/2, anti-cofilin, and anti-phospho-cofilin antibodies (Cell Signaling 
Technology). Image J (National Institutes of Health) was used to quantitate 
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densitometry for all blots. For drug treatment experiments, cells were incubated with 
the indicated concentrations of Y-27632 or Fasudil (EMD4 Biosciences) for 45 
minutes before collection. 
 
Statistical significance 
Statistical significance was calculated using a paired two-tailed Student's t 
test. 
 
Chapter V 
PBMC isolation 
Peripheral blood draws were performed using sodium citrate as an anti-
coagulant. The use of human material was approved by the UNC Institutional 
Review Board (IRB# 10-1595). 80mL of blood was diluted 1:1 with Hank’s Balanced 
Salt Solution (HBSS) (Gibco) containing 1mM EDTA and 0.5% BSA. The 
blood/HBSS solution was gently layered in a 1:1 ration on Histopaque-1077 (Sigma) 
in polypropylene centrifuge tubes. The tubes were then centrifuged at 400 x G for 30 
minutes at room temperature. After centrifuging, the upper plasma layer was 
aspirated and the distinct opaque layer at the plasma-Histopaque boundary 
containing PBMCs was transferred to new tubes and brought up to 50mL using 
EGM-2 (Lonza) supplemented with 50mL FBS and 5mL antibiotic/antimycotic 
(Gibco) (termed EGM-2C). The tubes were then centrifuged at 400 x G for 15 
minutes at room temperature. The supernatant was aspirated, and every 2 
pellets/tubes were combined into 1 and washed with EGM-2 for 10 minutes at 300 x 
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G at room temperature. The media was aspirated, then the pellets were re-
suspended in 50mL EGM-2C and centrifuged at 200 x G for 10 minutes in order to 
remove platelets. The pellets were then re-suspended and cell count was 
determined. 
 
Establishing and passaging EP-ECs 
Approximately 1 hour before PBMCs are isolated, a six well plate was coated 
with 50ug/mL type I collagen and 0.02N acetic acid solution. The plate was washed 
2x with HBSS and 20 x 10^6 PBMC were plated in each well in 2mL of EGM-2C and 
placed in an incubator at 37 °C with 5% CO2. After 72 hours supernatant was slowly 
aspirated and 2mL fresh media was added. Media was changed like this every day 
for 7 days, after which it was changed every second day. Colonies of cells with 
cobblestone morphology appeared in approximately 4 weeks, and these EP-ECs 
were passaged when the colonies expanded to cover 50-70% of the dish. EP-ECs 
were cultured so as to maintain high confluency and were subsequently passaged 
when they reached 95% confluency. 
 
Chapter VI 
Generating a three-dimensional model of CCM3 using multiple templates  
The modeling for Chapter 6 was performed by Dr. Sompop Bencharit of the 
UNC Departments of Dentistry and Pharmacology. The following protein structure 
prediction protocol was recently tested in the critical assessment of techniques for 
protein structure prediction (CASP8; <http://predictioncenter.org>). All predictions 
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with normalized RAPDF scores better than -55 (described below) were within 3.5 
Ångstrom root mean squared deviation of the corresponding experimental PDB 
structure, indicating correct overall topology. Additionally, the refinement method 
consistently improved initial models, in some cases resulting in models within the 
accuracy of the corresponding experimental structures themselves. 
 
Initial models 
The initial comparative modeling templates were identified using the 
secondary structure enhanced profile-profile threading alignment (LOMETS) and the 
four part iterative threading assembly refinement protocol of I-TASSER (151, 152). 
Ten different protein structure prediction servers were sampled, each producing at 
least five models. All those conforming, at least in part, to the selected templates 
(1kil, 1s35, 1sum, 1txd, 2boq, 2i0m, 2of3) were used in further analysis, along with 
five models produced by PROTINFO (153) from the two full length templates (1sum, 
2i0m). 
Iterations of ENCAD energy minimization and SCWRL3.0 sidechain 
optimization were applied to increase the sampled conformational space between 
models, such that variation and coverage were sufficient for clustering analysis. With 
the resultant model set, an iterative density calculation was applied, which cycles 
between a cluster density calculation and removal of outliers. Centroids for the five 
largest sub-clusters were then taken as the five input models for refinement. 
 
RAPDF and consensus based constraint selection 
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From the five initial models, a set of consensus interatomic distances was 
derived as all atom-atom pair distances that occur within a 0.5 Ångstrom window for 
at least four of the five models. RAPDF was used to score the consensus distances. 
Here the philosophy was that the probabilities derived from a Bayesian analysis of 
distances observed in a structurally non-redundant database of experimentally 
derived protein models versus random are likely to be useful to build models similar 
to the native state protein conformation (154). A batch-by-batch method compiled 
the final distance set, starting with the consensus distances having the highest 
RAPDF scores, resulting in a single interatomic distance for each possible residue 
pair in the protein. Each distance was weighted for importance in model building by 
the RAPDF score and whether the distance was observed in four or all of the five 
input models. Finally, three constraint sets were built using different maximal 
distance cutoffs (12 Å, 16 Å, 20 Å). 
 
Model building and final selection 
The three constraint sets were each used in fifty rounds of CYANA restrained 
torsion angle dynamics simulations, for which a Ramachandran plot-like distribution 
of torsion angles observed in the non-redundant structure database was used to 
prescribe probabilities for torsion angles (155). Each round produced twenty all-atom 
models, with a total of three thousand conformations created. Half of the 
conformations were filtered by sequentially applying RAPDF, a van der Waals 
energy term, the hydrophobic compactness factor, and an electrostatics term. The 
resulting models were minimized by ENCAD and SCWRL3.0, and subsequently the 
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iterative density calculation was again applied to cyclically remove outliers and re-
cluster, and finally to select the centroid for each of the five largest clusters. A new 
set of interatomic distances were obtained from the resulting five models, and used 
in a second round of consensus modeling that produced the final tertiary structure 
predictions. 
 
Homodimer interface site prediction 
Protein-protein interface sites were identified by applying the optimal docking 
area method (http://www.molsoft.com/oda), which segregates surface patches and 
applies atomic desolvation calculations parameterized with octanol/water transfer 
experiments adjusted to protein-protein interactions (156).  
 
Examination of phospholipid and CCM2 binding using recombinant CCM3 proteins 
Production of recombinant CCM3 protein was described previously (69). Full-
length murine CCM3 was amplified using PCR from a mouse fibroblast cDNA library 
and cloned into pMCSG7-His. Recombinant murine 6xHis-CCM3 was expressed in 
BL21 cells and purified by nickel affinity chromatography. Three mutants were 
generated using site-directed mutagenesis (QuikChange, Stragetagene) including 
two K-to-A mutations (∆2KA:K169A, and K172A), three K-to-A mutations 
(∆3KA:K179A, K183A and K186A), and five K-to-A mutants (∆5KA: K169A, K172A, 
K179A, K183A, and K186A). Similar to the wild type protein, mutant proteins were 
expressed with N-terminal 6xHis-tag in BL21DE3 cells. Membrane lipid arrays and 
PIP arrays were purchased from Echelon Biosciences. Membranes were blocked in 
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0.1% ovalbumin in TBS-T for one hour then incubated with 1 µg/ml of recombinant 
protein for two hours. After washing unbound protein using TBS-T, bound protein 
was detected by immunoblotting with an anti-His antibody (Santa Cruz 
Biotechnology).  
 
Pull-down experiments 
For pull-down experiments, vectors encoding FLAG-tagged CCM1 and CCM2 
were transfected into HEK293 cells using Lipofectamine (Invitrogen). Twenty-four 
hours after transfection, cells were harvested in a non-ionic detergent containing 
lysis buffer, and total protein concentration was determined by the Bradford method.  
10 µg His-tag recombinant wild type and mutant ∆5KA of CCM3 were bound to 
CNBr-activated sepharose beads (GE Biosciences) and incubated with 500 µg of 
cell lysate for 16 hours at 4ºC. Beads were collected by centrifugation and washed 
3x with lysis buffer. Washed beads were then mixed with 30 µL of 2x SDS-PAGE 
buffer and analyzed on a 10% polyacrylamide gel. FLAG-tagged and His-tag 
proteins were detected by immunoblotting as previously described (69). 
 
Size-exclusion chromatography-multi angle laser light scattering (SEC-MALS)  
0.2 to 0.4 mg/mL of purified His-tag recombinant wild type and ∆5KA CCM3 
were dialyzed in 10 mM phosphate buffer, pH 7.0 and 500 mM NaCl. The absolute 
molecular weight of each protein was determined using high-performance size-
exclusion chromatography (SEC-MALS) composed of Wyatt DAWN EOS light 
scattering instrument interfaced to an Amersham Biosciences Akta FPLC, Wyatt 
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Optilab refractometer, and Wyatt dynamic light scattering module at the UNC-CH 
Macromolecular Interaction Facility using methods similar to ones previously 
described (157, 158). 
 
Circular dichroism and thermal denaturation studies 
CD and thermal denaturation experiments were conducted using an Applied 
Photophysics PiStar-180 CD spectropolarimeter. Wild type or ∆5KA CCM3 (0.15 
mg/ml; in 10 mM phosphate buffer, pH 7.0) was used. CD data was collected for 
each protein and ranged in wavelength from 185 to 260 nm. For the thermal 
denaturation experiments, the temperature was increased from 25 °C to 90 °C while 
monitoring at 222 nm. Plots of fraction denatured versus temperature were produced 
by defining the upper and lower temperature baselines as 0 and 100%, respectively. 
 
Cell culture, immunostaining, and co-localization analysis 
COS7 cells were maintained in DMEM (LifeTechnologies) with 10 % FBS, 
100 U/mL penicillin, and 100 µg/mL streptomycin at 37 °C with 7 % CO2. 
Recombinant human IL-1β was obtained from PeproTech. Polyclonal anti-Myc 
antibody was obtained from Santa Cruz Biotechnology and FITC goat anti-rabbit 
antibody was obtained from Invitrogen. pBabe-p110-CAAX-Myc was generously 
provided by Dr. Channing Der (University of North Carolina). 
COS7 cells were transfected with wild type CCM3-mCherry, ∆5KA-ECFP, and 
p110-CAAX-Myc, and were plated on 22 mm square glass coverslips in a 6-well 
plate using Lipofectamine2000 as recommended by the manufacturer (Invitrogen). 
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After 24 hours, the cells on coverslips were fixed for 20 minutes with 4 % 
paraformaldehyde in PBS at 25 °C. Permeabilization was conducted using 0.1 % 
Triton X-100 in PBS for 10 min. Nonspecific binding was blocked by incubation of 
coverslips for 1 h in 10 % goat serum in PBS. The coverslips were incubated with 
polyclonal anti-Myc antibody (Invitrogen) for 1 hour and washed with PBS. Bound 
primary antibodies were visualized by incubation with FITC goat anti-rabbit antibody 
for 1 h, washed, and mounted on glass slides. Imaging was performed using a Zeiss 
Axiovert 200 M inverted microscope with a 125-W xenon arc lamp (Sutter Instrument 
Company, Novato, CA), digital CCD camera (CoolSNAP HQ, Roper Scientific, 
Tucson, AZ), and Slidebook 5.0 software (Intelligent Imaging Innovations, Denver, 
CO). An objective (63x Oil 1.25-numerical aperture, Plan-Neofluar, Zeiss) was 
coupled with immersion oil to the bottom face of glass coverslips. The images were 
obtained at 50 and 10 ms exposure with 2 x 2 binning, respectively. For section 
analyses, the background images from three planes were taken for each of the three 
channels (CFP (a band-pass excitation filter of 436/20 nm, a 455DCLP band 
beamsplitter, and a band-pass emission filter of 480/40 nm), YFP (a band-pass 
excitation filter of 500/20 nm, a 515DCLP band beamsplitter, and a band-pass 
emission filter of 535/30 nm), and Cy5 (a band-pass excitation filter of 620/60 nm, a 
660DCLP band beamsplitter, and a band-pass emission filter of 700/75 nm); 
Chroma). The three planes were deconvolved using the nearest neighbor’s 
algorithm. 
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Chapter VII 
Multiplexed inhibitor beads coupled with mass spectrometry 
 MIB-MS was performed as previously described by Duncan et al. (159). 
Briefly, cells were lysed in a low salt buffer containing 50 mM HEPES, 0.5% Triton 
X-100, 150 mM EGTA, 10mM sodium fluoride, 2.5 mM sodium orthovanadate, 1X 
protease inhibitor cocktail (Roche), and 1% each of phosphatase inhibitor cocktails 2 
and 3 (Sigma). To isolate protein kinases, lysates were run through columns of the 
following inhibitors covalently conjugated to beads: Bisindoylmaleimide-X, 
SB203580, Lapatinib, Dasatinib, Purvalanol B, VI16832, and PP58. Kinase-bound 
inhibitor beads were then washed with high and low salt buffers in 0.1% SDS, then 
eluted in 0.5% SDS and high heat. Chloroform/methanol extraction was used to 
purify proteins, followed by resuspension in 50 mM HEPES, followed by overnight 
digestion at 37 °C with trypsin. 
 A MALDI TOF/TOF 5800 (ABSCIEX) was used to acquire MS and MS/MS 
data. Data was analyzed with ProteinPilot Software (ABSCIEX) with a 
UniProtKB/Swiss-Prot database. Peptide quantitation was performed using the Pro 
Group algorithm and quantitation ratios were bias corrected. MIB-MS was performed 
by Rachel Reuther of the Johnson lab, and experiments were conducted in 
collaboration with Bryan Richardson of the Johnson lab. 
 
Western blotting 
 Western blotting was performed as described in the methods for chapter 3. 
Drug treatments were as follow: EGM2-C (Lonza) was supplemented with 10µM Y-
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27632 and HUVECs were incubated in this media for 24 hours, at which time fresh 
media containing 10µM Y- 27632 was added. Cells were harvested 24 hours later, 
for a total of 48 hours of ROCK inhibition. Inhibition was validated through Western 
blotting and MIB-MS. MG132 was also used at a final concentration of 10µM Y- 
27632 in media. Cells were treated for 12 hours with MG132 before lysis. 
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III. Rho kinase inhibition rescues the endothelial cell cerebral cavernous 
malformation phenotype in vitro 
 
Introduction 
 Cerebral cavernous malformations (CCM) are clusters of leaky, dilated 
capillaries in the central nervous system that occur in approximately 0.5% of the 
general population and up to 1.5% of the Hispanic population (160). CCM frequently 
lead to clinical sequelae such as hemorrhage, epilepsy and neurological deficits 
(160). The disease is associated with both germline and somatic mutations in one of 
three genes, CCM1, CCM2, or CCM3 (60). The three CCM proteins form a common 
complex indicating they function coordinately (23, 69); each lack defined catalytic 
domains indicating they are scaffold- or adapter-like proteins for organization of 
protein complexes (23, 69, 71). The identical disease phenotype produced upon loss 
of any one of the three CCM proteins suggests that they coordinately regulate a 
common mechanism required for vascular integrity (23, 32, 69, 85).   
It was recently shown that loss of endothelial cell expression of CCM2 
resulted in activation of the GTPase RhoA (32, 78). Crose et al. demonstrated that 
CCM2 knockdown in brain microvascular endothelial cells resulted in defective RhoA 
degradation because of the dysregulation of SMURF1, a CCM2 binding partner and 
an E3 ubiquitin ligase that controls RhoA degradation (78). RhoA overabundance 
induced by loss of CCM2 was shown to increase cytoskeletal stability, inhibit vessel-
like tube formation, and increase endothelial cell monolayer permeability (32, 78). 
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Herein, we show that loss of CCM1, -2 or -3 expression results in a common 
phenotype associated with RhoA overexpression and activation. We define ROCK 
as a critical RhoA effector whose increased activation dysregulates endothelial cell 
function. ROCK is activated by RhoA and phosphorylates several substrates, 
including myosin light chain, myosin light chain phosphatase, and LIM kinase for the 
regulation of actin cytoskeletal dynamics (90). ROCK has also been shown to 
regulate vascular permeability and has been a drug discovery target for regulation of 
vascular bed diseases (161). Our findings show that ROCK inhibition rescues 
extracellular matrix invasion and vessel-like tube formation, two endothelial cell 
functions disrupted by the loss of CCM protein expression. 
 
Results 
Knockdown of CCM1, -2 or -3 induces RhoA overexpression and persistent RhoA 
activity 
Expression of each of the three CCM proteins was selectively inhibited by 
short hairpin RNA (shRNA) knockdown in endothelial cells (Fig. 3.1, A and B). 
Stable knockdown of CCM1, -2 or -3 each resulted in 20-35-fold increases in RhoA 
expression relative to wild type cells (Fig. 3.2 A). The finding that inhibition of CCM1, 
-2 or -3 protein expression similarly caused marked increases in RhoA expression 
demonstrates for the first time that the three CCM proteins function coordinately to 
regulate RhoA protein levels; loss of any one CCM protein causes an increase in 
RhoA expression. Previously, we showed that CCM2 knockdown resulted in 
dysregulated SMURF1-mediated degradation of RhoA (78). The control of RhoA 
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protein levels requiring all three CCM proteins is consistent with the requirement of a 
functional protein complex of CCM1, -2 and -3 for regulating the degradation of 
RhoA. 
A RhoA biosensor based on FRET, which has been extensively characterized 
for measurement of activated RhoA in live cells (150, 162), was used to measure the 
spatial dynamics of RhoA activity in control and CCM1, -2 or -3 knockdown 
endothelial cells. The overexpression of RhoA observed in CCM knockdown cells 
results in a persistent activation of RhoA (Fig. 3.2, B and C). In wild type endothelial 
cells, RhoA activity is low and observed primarily at the cell edge as previously 
described for fibroblasts (150, 162). With shRNA knockdown of CCM2 or CCM3 
there is a significant increase in RhoA activity not only at the cell edge but also in the 
cytoplasm and nucleus. When a population of approximately 50 single cells is 
imaged and averaged for FRET intensity of the RhoA biosensor at the cell edge, 
cytoplasm or nucleus, the CCM1, -2 and -3 knockdown cells each have a highly 
statistically significant increase in RhoA activation relative to control cells (Fig. 3.2 D, 
see legend for p values). Strikingly, RhoA activity is extremely high in CCM1 
knockdown cells relative to control, CCM2 or CCM3 knockdown cells (Fig. 3.2 B). 
Statistical analysis of a population of individual CCM1 knockdown cells indicates an 
average of 1.6, 2.3, and 1.5-fold increase in FRET intensity relative to wild type cells 
for the cytoplasm, nucleus, and cell edge, respectively (Fig. 3.2 D). These findings 
indicate that CCM1 has a functional role as a negative regulator of RhoA activity, 
which is different from the regulation of RhoA protein expression that is a common 
function of the three CCM proteins. 
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ROCK2 is required for increased phosphorylation of myosin light chain 2 in CCM1, -
2 or -3 knockdown cells.  
ROCK1 and ROCK2 are closely related kinases with overlapping but also 
distinct functions (163). Both ROCK1 and ROCK2 bind activated GTP-RhoA (163). 
MLC2 is phosphorylated by ROCK1/2 and phospho-MLC2 is a measure of ROCK1/2 
activity in cells (90, 163). MLC2 is required for the control of actin cytoskeletal 
dynamics, induction of stress fiber formation, and cell contraction (90), whereby 
ROCK1/2 phosphorylation of MLC2 and MLC phosphatase leads to increased 
cytoskeletal stability (98, 163). 
We previously showed that stress fiber-associated phospho-MLC2 was 
increased in brain microvascular endothelial cells upon knockdown of CCM2 (78). 
Given the increased RhoA activity observed in CCM1, -2 or -3 knockdown 
endothelial cells (Fig. 3.1), we predicted that phosphorylation of MLC2 would be 
increased with knockdown of each of the CCM proteins. Phospho-MLC2 is indeed 
increased with loss of expression of each of the three CCM proteins (Fig. 3.3). In 
MEECs ROCK2 is the functionally predominant ROCK form and was targeted for 
shRNA knockdown. Loss of ROCK2 expression reversed the increase in phospho-
MLC2 observed in each of the CCM protein knockdown cell lines, demonstrating that 
ROCK2 stimulates the phosphorylation of MLC2 in MEECs (Fig. 3.3). 
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Knockdown of CCM1, -2 or -3 inhibits endothelial cell vessel-like tube formation and 
invasion of extracellular matrix.  
Knockdown of CCM1, -2 or -3 in endothelial cells results in the inhibition of 
extracellular matrix invasion and vessel-like tube formation (Fig. 3.4 and Fig. 3.5A). 
Even after 48 hours, whereas wild type cells organize into a well-formed tubule 
network, CCM1, -2 and -3 knockdown cells fail to form vessel-like tubes (Fig. 3.6A). 
The findings define a common phenotype for loss of each of the three CCM proteins 
with inhibition of invasion and vessel-like tube formation providing quantitative 
assays to define treatments to rescue the CCM pathology. Based on the common 
inhibition of invasion and vessel-like tube formation, and the increased ROCK2-
dependent increase in phospho-MLC2 with knockdown of each CCM protein, we 
reasoned that ROCK2 was a therapeutic target to reverse the CCM phenotype. 
 
CCM1, -2 or -3 knockdown pathology is rescued by inhibition of ROCK. 
Relevant to rescue of the CCM pathology, we previously demonstrated that 
the small molecule ROCK inhibitor Y-27632 rescued the inhibition of endothelial cell 
migration resulting from shRNA knockdown of CCM2 in a scrape wound healing 
assay with brain microvascular endothelial cells (78). Y-27632 or shRNA knockdown 
of ROCK2 was used to test the role of ROCK in rescuing the loss of endothelial cell 
invasion of extracellular matrix (Fig. 3.4). Importantly, knockdown of CCM1, -2 or -3 
did not affect ROCK2 expression nor did knockdown of ROCK2 affect expression of 
CCM1, -2 or -3 (Fig. 3.7). The inhibition of extracellular matrix invasion resulting from 
CCM1, -2 or -3 knockdown was rescued by either loss of ROCK2 expression or 
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treatment of cells with Y-27632 (Fig. 3.4). CCM1 knockdown cells were only weakly 
rescued by Y-27632 but strongly rescued by shRNA knockdown of ROCK2. This 
may in part be due to the time-dependent reversal of the strong CCM1 knockdown 
phenotype with Y-27632 (Fig. 3.2, Fig. 3.5B and see below). 
In vessel-like tube formation assays, time-lapse imaging of control versus 
CCM1, -2 or -3 knockdown endothelial cells showed that knockdown of ROCK2 or 
treatment of cells with Y-27632 to inhibit ROCK activity rescued vessel-like tube 
formation for each of the three CCM protein knockdown endothelial cell lines (Fig. 
3.6B and Fig. 3.5B-D). Analysis of multiple vessel-like tube formation assays 
indicated that the rescue of the CCM pathology, as measured by the increase in 
mean tube area, was greater with shRNA knockdown of ROCK2 compared to Y-
27632 (Fig. 3.5E and Fig. 3.6B). Analysis of the time-lapse images indicated that the 
onset of vessel-like tube formation was delayed several hours with treatment of 
CCM1, -2 or -3 knockdown cells with Y-27632 compared to vessel-like-tube 
formation with control or ROCK2 knockdown cells (Fig. 3.5B-D). This finding is 
similar to the reduced rescue of extracellular matrix invasion in CCM1 knockdown 
cells treated with Y-27632 compared to shROCK2 (Fig. 3.4) and is likely due to the 
time required for chemical inhibition of ROCK and reversal of the ROCK-mediated 
changes in cellular physiology. 
 
Y-27632 treatment induces endothelial cell shape changes required for vessel-like 
tube formation in CCM1, -2 or -3 knockdown cells.  
Loss of ROCK2 expression by targeted shRNA knockdown inhibits the 
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activated RhoA stimulation of MLC2 phosphorylation (Fig. 3.3). Hence, rescue of the 
in vitro CCM pathology caused by loss of one of the three CCM proteins, as 
measured by vessel-like tube formation and invasion of extracellular matrix, is 
essentially complete and the cells behave similar to control cells. Y-27632 rescue of 
the CCM pathology is similar to shRNA knockdown of ROCK2. Pharmacological 
ROCK2 inhibition reverses pathways controlled by ROCK2 that contribute to the 
CCM1, -2 or -3 knockdown phenotype. In a subpopulation of CCM1, -2 or -3 
knockdown endothelial cells incubation with Y-27632 induces a time-dependent 
change in cell shape involving cell flattening and the extension of multiple membrane 
protrusions (Fig. 3.8). The cell shape changes are evident after one-hour treatment 
with Y-27632 and by 4 hours these cells are forming nucleation centers for the 
initiation of tube formation (Fig. 3.8, arrowhead). CCM knockdown cells in the 
absence of Y-27632 are unable to undergo significant cell shape change and extend 
only small filipodial-like structures (Fig. 3.8, arrows). In contrast, pLKO.1 knockdown 
cells do not undergo the shape changes induced by Y-27632 because ROCK2 is not 
activated and driving constitutive RhoA control of the actin cytoskeleton (98, 163). 
Consistent with these observations is the fact that loss of ROCK2 expression in both 
control cells and CCM protein knockdown cells causes formation of well-defined 
vessel-like tubes 4 hours after initiating the assay (Fig. 3B-D). The findings indicate 
that ROCK2 actively drives the CCM pathology characterized by inhibition of 
invasion of extracellular matrix and vessel-like tube formation. 
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Discussion 
The three CCM genes are scaffold or adaptor proteins capable of forming a 
CCM1-2-3 protein complex for organization of proteins involved in regulating the 
cytoskeleton (69, 71). Thus, the molecular basis of CCM is fascinating in that the 
loss of function of a scaffold or adaptor protein is sufficient to develop the pathology 
(32, 71, 85). The function of CCM proteins was further elucidated by the discovery 
that RhoA becomes overexpressed with loss of CCM2 expression (32, 78), and that 
CCM2 regulates RhoA protein level by controlling its degradation (78). We have now 
shown that CCM1 and -3 proteins in addition to CCM2 are required for regulation of 
RhoA protein levels, and loss of CCM1, -2 or -3 each results in the pronounced 
increase in expression of RhoA. This result supports the critical role of the CCM 
protein complex in controlling RhoA expression. The RhoA biosensor allowed 
measurement of live cell images for RhoA activity in control and CCM1, -2 and -3 
knockdown cells. Clearly, RhoA activity is increased with loss of CCM1, -2 or -3 
proteins and the increased RhoA activity results in changes in regulation of ROCK 
and the cytoskeleton. The pronounced RhoA activity with CCM1 knockdown strongly 
suggests that CCM1 has a function controlling a Rho guanine nucleotide exchange 
factor or Rho GTPase activating protein. This difference suggests a function specific 
for CCM1 relative to CCM2 or -3. However, the effect of CCM1 loss of expression 
was not generally different than what was observed with loss of CCM2 or -3 
expression for changes in phospho-MLC2 levels or dysregulation of invasion or 
vessel-like tube formation. We have proposed that CCM proteins localize signaling 
complexes to specific cellular locations associated with actin reorganization (69, 78). 
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This would suggest CCM proteins spatially control RhoA degradation for regulating 
specific physiological functions. Interestingly, activation of Rho GTPases and ROCK 
has also been observed in Smith-Lemli-Opitz syndrome, suggesting that 
dysregulation of this signaling axis has major pathophysiological implications in 
different human diseases (15). 
Surgical resection is currently the standard treatment for symptomatic CCM, a 
highly invasive procedure with significant risk to the patient (164). In addition, lesions 
located in critical areas such as the brainstem or basal ganglia are more likely to 
exhibit a poor natural history, yet no treatment exists because they are surgically 
inaccessible. The discovery that inhibition of ROCK, a kinase activated by RhoA, is 
able to rescue dysregulated endothelial cell physiology resulting from loss of CCM1, 
-2 or -3 expression provides, for the first time, a pharmacological approach using a 
small molecule kinase inhibitor for treatment of CCM. The function of RhoA and 
ROCK in promoting vascular permeability is consistent with the dysregulated RhoA-
ROCK signaling axis being important in promoting CCM pathology. Thus, ROCK 
inhibitors are clearly potential therapeutics for the treatment of CCM. Studies have 
shown that two ROCK inhibitors, Fasudil and Y-27632, are reasonably well tolerated 
in animals (165). In fact, Fasudil has been used in Japan for treatment of cerebral 
vasospasm following subarachnoid hemorrhage since 1995, indicating ROCK 
inhibitors can be tolerated in humans (166). 
Given that the RhoA-ROCK signaling axis is clearly dysregulated in CCM, 
there is still much to learn about the RhoA activation and inactivation cycle and how 
it is dysregulated in CCM endothelial cells. Questions also remain regarding the 
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CCM protein complex and control of signaling networks including the potential 
involvement of additional kinases that could contribute to the CCM pathology and be 
pharmacologically targeted for treatment of CCM. For example, MEKK3, a MAP3K 
that regulates ERK5, JNK and NFkB, is in the CCM protein complex and is important 
for regulating responses to inflammatory cytokines such as IL-1 (69, 167). 
Significantly, it appears a pharmacological small molecule treatment to control CCM 
is a real possibility. 
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Figure 3.1: Quantitation of shRNA knockdown of CCM expression. (A) Expression of 
CCM1, -2, and -3 mRNA in stable lentiviral shRNA infected cells. Expression of 
CCM1, -2, and -3 mRNA in shCCM1, -2, and -3 cells are knocked down by 70, 96 
and 95% relative to pLKO.1 cells, respectively. Real-Time PCR was used to 
measure expression levels and data are the means ± SEM of three independent 
experiments performed in triplicate. (B) Western blot of wild type and shCCM2 cells 
showing that CCM2 protein expression is lost in shCCM2 cells. 
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Figure 3.2: RhoA abundance and activity are increased in shCCM1, -2 or -3 
endothelial cells. (A) Western blot showing that the abundance of RhoA in shCCM1, 
-2 or -3 cells is increased 23, 37 and 28-fold relative to wild type cells. (B) Wild type, 
shCCM1, -2 or -3 cells were infected with FRET-based RhoA biosensor, where 
activation of RhoA leads to FRET. The measured FRET signal has been 
pseudocolored, where blue indicates low FRET and low RhoA activity, and red/white 
indicate high FRET and high RhoA activity. shCCM1 cells display the greatest RhoA 
activity, which is especially high in the nucleus. RhoA activity is increased at cell 
protrusions and nucleus of shCCM2 and shCCM3 endothelial cells. (C) Active RhoA 
at the cell periphery and nucleus of shCCM2 is shown in detail. (D) Bar graph 
showing the fold change in FRET intensity for the cytoplasm and nucleus of 
shCCM1 (1.62 and 2.33 respectively), shCCM2 (1.16 for both) and shCCM3 (1.23 
for both) relative to wild type. Data represents the mean ± SEM for minimum of 25 
cells in two independent experiments. Error bars ***p<0.001, **p<0.02, *p<0.05. 
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Figure 3.3: Western blot shows an increase in phospho-MLC2 in shCCM1, -2 or -3 
endothelial cells, which is lost upon shRNA knockdown of ROCK2. Bar graph shows 
densiometric quantitation of band intensity. The abundance of phospho-MLC2 in 
shCCM1, -2 or -3 cells increases respectively 1.9, 3.5 and 1.2-fold relative to control 
pLKO.1 cells. Upon shRNA knockdown of ROCK2, the abundance of phospho-
MLC2 decreases respectively below detectable levels, 80 and 80% for shCCM1, -2 
or -3 relative to levels prior to shROCK2 treatment. 
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Figure 3.4: Invasion is decreased in shCCM1, -2 or -3 endothelial cells and rescued 
by ROCK inhibitor Y-27632 or shRNA for ROCK2. (A) shCCM1, -2 or -3 cells were 
seeded in the top of a Boyden chamber invasion chamber. Cells invaded to the 
bottom of the membrane were stained with rhodamine-phalloidin and imaged. Five 
images per membrane were taken and one image per condition is shown. Invasion 
of shCCM1, -2 or -3 cells is decreased relative to wild type, but rescued upon 
treatment with 10µM Y- 27632 or upon shRNA knockdown of ROCK2. (B) Bar graph 
showing the fold change in the number of invaded shCCM cells relative to pLKO.1. 
Invasion in shCCM1, -2 or -3 cells is decreased respectively 70%, 70% and 60% 
relative to pLKO.1 cells. Data represents mean ± SEM for minimum of three 
independent experiments. Error bars ***p<0.001, **p<0.02, *p<0.05. 
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Figure 3.5: ROCK inhibitor Y-27632 and ROCK2 shRNA rescue tube formation in 
shCCM1, -2 or -3 endothelial cells. (A) Knockdown of CCM1, -2, or -3 results in loss 
of tube formation. Image is a 9-panel montage of 10x frames, and bar represents 
300µm. (B) Tube formation in shCCM1 cells can be rescued with Y-27632 (+Y) or 
shROCK2 (+shR). Frames are taken at 0, 1, 3, 5, and 15 hours after start of 
treatment with Y-27632. Bar represents 100µM. Image is a single 10x field. (C) Tube 
formation rescue in shCCM2 cells by shROCK2 or Y-27632. (D) Tube formation 
rescue in shCCM3 cells by shROCK2 or Y-27632. (E) Bar graph represents mean 
tube area of pLKO.1 and shCCM1, -2, and -3 cells, normalized to pLKO.1. The data 
are the means ± SEM of 6 frames from at least three independent experiments. 
***p<0.001, **p<0.02, *p<0.05. 
 
 
 67 
 
 
Figure 3.6: Tube formation in shCCM1, -2, and -3 endothelial cells is rescued by 
shROCK2 or Y-27632 treatment. (A) Tube formation in shCCM1, -2, and -3 cells is 
not rescued with extended incubation. At 48 hours, cells congregate but still fail to 
form tubes. Cells die and detach after 48 hours. Image is a 9-panel montage of 10x 
fields, and bar represents 300µM. (B) Y-27632 and shROCK2 rescue tube formation 
in CCM1, -2, and -3 knockdown cells. Image is a 9-panel montage of 10x fields, and 
bar represents 300µM. 
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Figure 3.7: Expression levels of CCM1, -2, -3, and ROCK2 in single and double 
knockdown stable cell lines. Knockdown was achieved through lentiviral shRNA and 
was measured by Real-Time PCR. Data are the means ± SEM of three independent 
experiments performed in triplicate and normalized to empty vector (pLKO.1) cells. 
(A) Expression of ROCK2 in shCCM1, -2, and -3 cell lines. (B) Expression of CCM1, 
-2, and -3 in shCCM/shROCK2 cells. CCM1, -2, and -3 knockdown is 50, 92, and 95 
%, respectively. ROCK2 knockdown is 79, 68, and 81% in shCCM1/shROCK2, 
shCCM2/shROCK2, and shCCM3/shROCK2 cells, respectively. 
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Figure 3.8: CCM1, -2, and -3 knockdown endothelial cells generate filopodia but are 
unable to form lamellipodia and undergo cobblestone to cuboidal transition. 
Migration is also impaired. Data shows images of cells taken at approximately 1 and 
4 hours. shROCK2 and Y-27632 rescue tube formation. Arrow denotes filopodia and 
arrowhead denotes cells with pronounced membrane protrusions that form 
nucleation centers for tube formation. Bar represents 50µM. 
 
 
 
 
 
 
 
 
IV. The Cerebral Cavernous Malformation proteins regulate the LIM kinase-
cofilin signaling axis in endothelial cells 
 
Introduction 
Cerebral Cavernous Malformations (CCM) are clusters of leaky, dilated 
capillaries that can cause seizures, neurologic deficits, and hemorrhagic stroke. 
CCMs occur in approximately 0.5% of Caucasians and 1.5% of Hispanics, with a 
mean age of 34 at presentation (60, 160, 168, 169). CCMs can be either sporadic or 
familial, and are caused by bi-allelic loss in endothelial cells of one of three genes: 
CCM1, CCM2, or CCM3 (25, 160, 170). The only treatments for CCM are surgical 
resection or radio-ablation, therefore the current standard of care is observation until 
symptoms necessitate intervention (3, 164). Furthermore, symptomatic lesions are 
often located in either eloquent tissue or surgically inaccessible areas (171). Thus, 
development of a pharmacological treatment for CCM is greatly needed. 
While the mechanism of CCM lesion development remains incompletely 
characterized, the similar biochemical and phenotypic abnormalities seen with loss 
of any of the 3 CCM proteins suggests that they coordinately regulate a common 
mechanism for maintaining vascular integrity. Recent work suggests that the CCM 
proteins maintain vascular integrity in part by regulating the actin cytoskeleton in 
endothelial cells (85, 172, 173). Crose et al. showed that CCM2 binds the E3 
ubiquitin ligase SMURF1 and localizes it to the membrane, where it functions to 
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degrade the small GTPase RhoA (78). Furthermore, the CCM proteins form a 
complex, and loss of CCM1, -2 or -3 by shRNA knockdown results in significantly 
elevated RhoA levels in endothelial cells (69, 172). Not only is total RhoA increased, 
but it is also persistently active (172, 174). RhoA is an important upstream regulator 
of actin, affecting cytoskeletal dynamics through the scaffold protein Mammalian 
Diaphanous (mDia) and the serine/threonine kinase Rho kinase (ROCK) (93). 
Activated ROCK positively regulates actin polymerization through two pathways: 
Myosin Light Chain Phosphatase (MLCP)-Myosin Light Chain 2 (MLC2), and LIM 
kinase (LIMK)-cofilin (96-98). We and others recently showed that levels of phospho-
MLC2 were increased in cells lacking the CCM proteins, and that CCM knockdown 
Endothelial cells displayed defects in tube formation, invasion, and monolayer 
barrier formation (172, 174). Significantly, these biochemical and functional defects 
can be rescued by shRNA knockdown or pharmacological small molecule inhibition 
of ROCK. Taken together, these findings suggest that gain of function of RhoA-
ROCK signaling leading to increased cytoskeletal stability through loss of 
cytoskeletal turnover is a driver contributing to CCM pathophysiology. ROCK and 
ROCK effectors are intriguing targets for CCM disease because the pharmacological 
ROCK inhibitor Fasudil is well tolerated in humans and has been used in Japan for 
the treatment of cerebral vasospasm since 1995 (175, 176). Additionally, Fasudil 
and other potent ROCK inhibitors such as Y-27632 and H-1152 are well tolerated in 
mice (145, 177). 
The relationship between the CCM proteins and LIMK-cofilin signaling has not 
been established. Since LIMK has been characterized as a ROCK effector in 
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endothelial cells, we hypothesize that the gain of function in the RhoA-ROCK axis 
will cause increased LIMK phosphorylation and increased LIMK-cofilin signaling 
activity. LIMK is a negative regulator of the actin depolymerizing factor cofilin (114). 
When phosphorylated by LIMK, cofilin’s actions on actin severing and monomer 
dissociation are decreased, leading to increased actin fiber stability and 
accumulation of F-actin(117, 118). Increased LIMK1-dependent cofilin 
phosphorylation was demonstrated as a key pathway for RhoA-mediated increase in 
microvascular permeability following acute lung injury (124). LIMK1 knockdown 
enhanced endothelial barrier function, suggesting that increased LIMK1-cofilin 
signaling due to RhoA increase could play an important role in pathological 
conditions involving loss of vascular integrity, such as CCM. 
Our findings define ROCK dysregulation resulting from loss of the CCM 
proteins. For the first time, we show that phospho-cofilin is increased in endothelial 
cells in lesions from human patients with CCM1, -2, and -3 mutations. Together with 
previous work demonstrating increased phospho-MLC2 in human lesions, this data 
shows that ROCK cytoskeletal regulatory pathways are severely dysregulated in 
CCM disease. Furthermore, we demonstrate that pharmacological inhibition of 
ROCK normalizes phospho-LIMK and phospho-cofilin levels in CCM knockdown 
endothelial cells, and that LIMK knockdown normalizes functional defects due to loss 
of the CCM proteins. Overall, cumulative findings in analysis of patient CCM lesions 
and RNAi studies indicate that dysregulation of RhoA-ROCK signaling is a major 
pathological mechanism in CCM disease. 
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Results 
 
RhoA-ROCK-dependent regulation of cofilin is dysregulated upon loss of the CCM 
proteins in human endothelial cells 
Immunofluorescence and Western blotting were used to define the effect of 
loss of CCM protein on RhoA-ROCK signaling. Stable shRNA-mediated knockdown 
of CCM1, -2, or -3 in human endothelial cells leads to increased phospho-cofilin, 
phospho-MLC2 and total actin, showing significant dysregulation of ROCK effectors 
and the actin cytoskeleton (Fig. 3.1A-E). CCM knockdown cells display increased 
cell area compared to pLKO.1 control endothelial cells, a phenotype consistent with 
increased RhoA-ROCK signaling (Fig. 3.1F). Indeed, Western blotting demonstrates 
an increase in total RhoA with loss of all 3 CCM proteins in human cells. Overall, we 
have demonstrated gain-of-function in RhoA resulting from loss of the CCM proteins, 
leading to significantly increased phosphorylation of two ROCK-controlled 
cytoskeletal effector arms. Increased RhoA leads to increased phospho-ROCK, 
which can be measured by phosphorylation of LIMK and MLC2. Increased phospho-
LIMK results in increased phospho-cofilin. Physiologically, the increase in phospho-
cofilin predictably leads to a decrease in actin turnover and the increase in phospho-
MLC2 leads to increased actin fiber stability. The cumulative effect would result in 
increased actin cytoskeleton stability. Indeed, loss of CCM1, -2, or -3 protein in 
human or mouse endothelial cells leads to an increase in total actin fiber abundance 
and cell area. Together, this data indicates substantial dysregulation of cytoskeletal 
regulators resulting from knockdown of the CCM proteins. High levels of stable 
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knockdown were achieved in all cell lines used in these experiments (Fig. 3.2). 
 
Loss of CCM1, -2, or -3 protein results in increased phospho-cofilin in vitro and in 
surgically resected human CCM lesions 
To define the role of the ROCK-LIMK-cofilin pathway in CCM pathogenesis, 
phospho-cofilin levels were measured in the context of loss of the CCM proteins. 
Phospho-cofilin was significantly elevated in stable CCM knockdown mouse 
embryonic endothelial cells (MEEC), as measured by 3,3’-Diaminobenzidine (DAB) 
immunohistochemistry of parafinized cell blocks (Fig. 3.3A). Cell blocks were also 
stained and immunofluorescence followed by Advanced QUantitative Analysis 
(AQUA) was performed (Fig. 3.3B). AQUA revealed a statistically significant 
increase in cofilin phosphorylation (Fig. 3.3C).  
Phospho-cofilin levels were also measured in surgically resected CCM 
lesions from patients with PCR-confirmed CCM1, -2, and -3 mutations (Table 3.1). 
Both immunohistochemistry and immunofluorescence show that phospho-cofilin is 
significantly increased in the endothelial monolayer of CCM lesions compared to 
normal brain tissue controls (Fig. 3.4A and B). CCM pathology is thought to develop 
through loss of CCM proteins in endothelial cells and not the surrounding 
parenchyma, thus a CD31 (Platelet Endothelial Cell Adhesion Marker 1) mask was 
used to define the endothelial monolayer in the CCM lesion. AQUA, an automated 
scoring system for assessing biomarker expression in tissue sections, was used to 
quantitate intensity of phospho-cofilin within the CD31 mask, normalized to control 
(Fig. 3.4C). The hyperphosphorylation of cofilin observed in human lesions follows a 
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similar pattern as phospho-MLC2 staining shown by Stockton et al., together 
showing a profound dysregulation of ROCK signaling in endothelial cells lining CCM 
lesions. These data demonstrate that phospho-cofilin is a robust biomarker for CCM 
disease and loss of CCM protein in endothelial cells. 
 
Pharmacological inhibition of ROCK decreases LIMK, cofilin, and MLC2 
hyperphosphorylation in human and mouse CCM knockdown endothelial cells 
In order to define the effect of small molecule ROCK inhibition on LIMK-cofilin 
signaling in CCM knockdown endothelial cells, phospho-protein levels were 
measured in CCM knockdown mouse and human endothelial cells treated with 
increasing concentrations of the structurally distinct small molecule ROCK inhibitors 
Fasudil and Y-27632. Phospho-LIMK is elevated with loss of the CCM proteins, 
confirming that increased ROCK activity leads to hyperactivation of a second 
signaling arm in CCM (Fig. 3.5A). 10µM drug treatment significantly decreased the 
elevated phospho-LIMK and phospho-cofilin seen with CCM1, -2, or -3 knockdown 
(Fig. 3.5A and B). Western blotting shows that phospho-cofilin is increased with loss 
of the CCM proteins, and is decreased with ROCK inhibition, reflecting the drug’s 
effects on LIMK phosphorylation (Fig. 3.5B). To further define the pharmacological 
effect of ROCK inhibition, CCM2 knockdown endothelial cells were treated with 
logarithmically increasing doses of Fasudil and phosphorylation of cofilin and MLC2 
was measured. CCM1, -2, or -3 knockdown leads to similar increases in 
phosphorylation of cofilin and MLC2, and phosphorylation of both decreases with 
increasing concentration of drug (Fig. 3.5C and D). These data suggest that the 
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RhoA-ROCK gain of function seen with loss of CCM proteins similarly affects MLC2 
and cofilin phosphorylation, and pharmacological inhibition has similar effects on 
decreasing hyperphosphorylation. The effectiveness of Fasudil in decreasing 
phospho-cofilin in vitro, along with its acceptable safety profile in humans and the 
markedly increased phospho-cofilin in human lesions, suggests that Fasudil would 
be a candidate for early stage clinical investigation. ROCK inhibition would not be 
expected to prevent lesion formation or promote regression, but could be used 
therapeutically to prevent vascular leak and subsequent hemosiderin deposition, 
which are thought to be the primary causes of clinical symptoms. 
 
LIMK and cofilin hyperphosphorylation is associated with decreased tube formation 
and invasion, and LIMK1 knockdown is sufficient to rescue this CCM phenotype 
To characterize the role of LIMK in the CCM endothelial cell phenotype, 
stable shRNA-mediated LIMK/CCM double knockdown endothelial cells were 
created and functional ability was compared with pLKO.1 control and CCM 
knockdown endothelial cells. High levels of LIMK1 knockdown were achieved, and 
this corresponded to a statistically significant decrease in both phospho-LIMK and 
phospho-cofilin, without affecting total cofilin abundance (Fig 3.6 A and B). CCM1, -
2, and -3 knockdown results in loss of tube formation and invasion in endothelial 
cells, which we previously showed can be rescued by ROCK inhibition. Significantly, 
LIMK1 knockdown in CCM1, -2, and -3 knockdown endothelial cells rescues vessel-
like tube formation and invasion to a similar level as chemical ROCK inhibition (Fig. 
3.6C). This data indicates that LIMK-cofilin hyperactivation is sufficient to cause the 
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CCM phenotype in vitro, and that the LIMK arm of ROCK signaling may play a more 
important role in CCM pathophysiology than the MLC2 arm. 
In order to further interrogate the arms of the ROCK signaling pathway, 
CCM2 and LIMK1 double knockdown cells were created. Similar to what is observed 
with tube formation, knockdown of LIMK in shCCM2 cells results in a statistically 
significant rescue of invasion through Matrigel (Fig. 3.7A). The ability of LIMK 
knockdown to rescue tube formation was compared to rescue from chemical ROCK 
inhibition and found to be very similar, supporting the idea that LIMK-cofilin 
hyperactivation is driving the observed defects in tube formation (Fig. 3.7B). A 
timecourse of tube formation shows the rescue ability of ROCK inhibition and LIMK1 
knockdown on shCCM2 endothelial cells (Fig. 3.7C). CCM2 knockdown cells form 
tubes poorly compared to pLKO.1 control cells. Most shCCM2 cells display a 
rounded phenotype throughout the timecourse, whereas pLKO.1 control cells flatten 
and form early tube structures by 4 hours. Both ROCK inhibition and LIMK1 
knockdown in CCM2 knockdown endothelial cells restore tube formation. The 
rounded phenotype and lack of motility displayed by the CCM2 knockdown 
endothelial cells suggest increased actin cytoskeleton stability, as would be 
predicted from increased phospho-MLC2 and phospho-cofilin. This stability 
decreases the ability of endothelial cells to undergo the morphological changes 
necessary for tube formation, which may reflect a component of the mechanism for 
CCM pathophysiology. Filapodia formation is unaffected, suggesting that Rac 
activity is not perturbed by high RhoA activity in CCM knockdown cells. 
Biochemically, CCM2 knockdown cells display increased total RhoA, and high 
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ROCK activity manifested by 2 to 3-fold elevation of phospho-LIMK, phospho-cofilin, 
and phospho-MLC2. As would be predicted, LIMK1 knockdown selectively 
decreases cofilin phosphorylation, while not affecting phospho-MLC2 (Fig. 3.7D and 
E). This indicates that LIMK-cofilin signaling plays a crucial role in causing the CCM 
phenotype, and suggests that elevated phospho-cofilin is sufficient to cause the in 
vitro CCM phenotype, while elevated phospho-MLC2 may be more of a readout for 
ROCK activity.  
 
Discussion 
The recent finding that the CCM proteins regulate RhoA-ROCK-LIMK 
signaling suggests a strong cytoskeletal component to CCM disease. ROCK 
inhibition rescues the CCM phenotype, giving hope that a pharmacological inhibitor 
such as Fasudil may be capable of treating CCM. We have now shown that a 
second ROCK axis is dysregulated in CCM, and further elucidated the mechanism of 
ROCK inhibition on CCM biochemistry and phenotype rescue. Stockton et al. 
recently showed elevated phospho-MLC2 in human lesions, and our data show 
significant dysregulation of a second important ROCK pathway. Together, these 
findings reveal significant biochemical dysregulation of cytoskeletal regulators in 
endothelial cells with CCM mutation. 
Given that CCM clinical symptoms are thought to result from vascular leak, 
we propose a mechanism of disease whereby endothelial cells lacking any one of 
the CCM proteins cannot properly maintain vascular integrity because of 
inappropriately activated ROCK signaling. We propose a model where both 
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LIMK/cofilin and MLCP/MLC2 play important roles in CCM pathophysiology. These 
roles are distinct, although overall both likely contribute significantly to formation of 
CCM lesions. Overactivation of LIMK and thus negative regulation of cofilin results in 
decreased actin depolymerization (99, 112). Inhibition of MLCP and thus increased 
phospho-MLC2 favor increased stress fibers (100, 178). Together, activation of 
these ROCK pathways decreases the ability of endothelial cells to remodel the 
cytoskeleton. Defects in invasion, tube formation, and monolayer barrier function are 
consistent with increased actin stability, contributing to the endothelial loss of 
function characteristic of CCM. Understanding the relationship between the CCM 
proteins and LIMK-Cofilin signaling gives insight to the therapeutic mechanism of 
ROCK inhibition. Future studies should further define the relative contributions of 
both ROCK pathways to CCM pathology. It is unknown whether the increased 
phospho-MLC2 levels resulting from loss of the CCM proteins are simply a readout 
for ROCK activity, or a driver of cell dysregulation. 
Our lab previously showed that the CCM proteins can bind in a complex, and 
that loss of any one leads to elevated total and active RhoA, along with similar 
phenotypes in in vitro endothelial cell functional assays. We also demonstrated 
increased phospho-MLC2 in shCCM1, -2, and -3 endothelial cells, and showed that 
phospho-MLC2 and functional defects could be normalized by ROCK inhibition, 
suggesting that all three CCM proteins similarly affect the ROCK cytoskeletal 
regulatory pathway. However, recent work has shown that CCM3 regulates other 
important pathways, including interactions with the Ste20 kinases GCK-3 and MST4, 
and angiogenesis through stabilization of VEGFR2 (179-182). Additionally, the 
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increase in RhoA-mediated ROCK signaling we reported with loss of CCM3 has not 
been replicated, leading to some suggestions that CCM3 mutations cause CCM 
disease through a separate pathway. It is unsurprising that CCM3 regulates 
pathways unique from the other CCM proteins, given that different binding partners 
have been demonstrated for each protein. Yet by showing increased phospho-cofilin 
in both human CCM3 mutant and mouse knockdown endothelial cells and thus 
showing dysregulation of a second arm of ROCK signaling, we clearly demonstrate 
that CCM3 ultimately regulates ROCK signaling in a similar manner to CCM1 and -2. 
Additionally, we are the only group to use stable shRNA knockdown of CCM 
proteins, rather than transient siRNA. We believe that assaying for RhoA-ROCK 
activity one to two weeks after knockdown is more reliable than 48 to 96 hours, 
given that changes in protein quantity and activity may not be apparent immediately. 
Furthermore, CCM3 is a significantly more stable protein than CCM1 or -2, being 
more compact and homodimerizing in native form. 
Further exploration of RhoA and ROCK targets is necessary to continue to 
understand the biology of the CCM proteins. mDia is an important cytoskeletal 
regulatory protein controlled by RhoA, and may be dysregulated in CCM. Similarly, 
Citron kinase is regulated by ROCK and plays an important role in cytokinesis and 
actin polymerization (183, 184). It would not be surprising if Citron kinase is 
overactive in CCM, and normalization is part of the rescue mechanism of ROCK 
inhibition.  
Questions also remain about the role of the CCM protein complex and its 
interaction with other signaling networks that could serve as therapeutic targets for 
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treatment of CCM. Yet while the CCM signaling pathway continue to be elucidated, 
little progress has been made on demonstrating the molecular mechanism whereby 
loss of CCM protein leads to lesion formation. Recent work showed that Fasudil 
treatment lessened vascular leak in peripheral vasculature in mice, and Fasudil’s 
clinical efficacy in treating cerebral vasospasm makes it a leading candidate for the 
first CCM therapy in clinical trial. Furthermore, this data suggests that LIMK is a 
therapeutic target for CCM, and in fact is a more specific target than ROCK. While 
there are presently no commercially available LIMK inhibitors, a number of specific 
and non-toxic LIMK inhibitors have been synthesized and shown to decrease 
phospho-cofilin levels (185, 186). LIMK hyperactivation has been implicated in 
several prevalent diseases such as hypertension and cancer, and therefore there is 
strong interest from pharmaceutical companies in developing therapeutic small 
molecule inhibitors (145, 187). If and when these compounds become available, 
they should be evaluated for efficacy in treating CCM disease.  
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Figure 4.1: Knockdown of CCM1, -2, or -3 leads to cytoskeletal dysregulation in 
human endothelial cells. (A-E) HUVECs were stained for phospho-cofilin or 
phospho-MLC2 (red), actin stress fibers (green) and nuclei (blue). CCM knockdown 
endothelial cells show increased phospho-cofilin, phospho-MLC2, and actin fibers 
compared to pLKO.1 control endothelial cells. N=2, ***p<0.001. (D) CCM1, 2, and -3 
knockdown cells display significantly increased area relative to pLKO.1 cells. N=2, 
***p<0.001. 
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Figure 4.2: Generation of stable shRNA knockdown endothelial cells. (A) LIMK1 
knockdown was performed in shCCM2 cells to make double knockdown lines. (B) 
shCCM2 and shCCM2/shLIMK cells do not display altered levels of LIMK2 message. 
(C) shRNA was used to create CCM2, LIMK1, and CCM2/LIMK1 double knockdown 
bEND.3 cells. (D-F) CCM/LIMK1 double knockdown lines were generated in 
MEECs. (G) Knockdown of CCM1, -2, or -3 message did not affect LIMK2 
expression. 
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Figure 4.3: Phospho-cofilin is increased in CCM1, -2, and -3 knockdown MEECs. (A) 
DAB of pLKO.1 control vs CCM knockdown endothelial cells. (B) 
Immunofluorescence of pLKO.1 and CCM knockdown MEECs, with Cy3-Tyramide 
and DAPI staining. (C) AQUA quantitation showing loss of CCM protein increases 
phospho-cofilin levels approximately 2-fold. N=2, *p<0.05, error bars represent SEM. 
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Figure 4.4: Phospho-cofilin is increased in human CCM lesions. (A) 
Immunohistochemistry for phospho-cofilin (brown) of normal brain vasculature and 
surgically resected lesions from confirmed CCM1, -2, and -3 mutation carriers. 
Arrows denote the endothelial monolayer and asterisks mark vessel lumen. Note 
that the CCM3 lesion demonstrates both the mulberry structure of early CCM lesions 
and the dilated structure of more evolved lesions. Scale bar is 100µM. (B) Phospho-
cofilin and CD31 staining of lesions from CCM mutation carriers demonstrates 
increased phospho-cofilin in CCM mutant endothelial cells. (C) AQUA shows 5-10-
fold increase in phospho-cofilin in CCM lesions, relative to normal brain vasculature. 
(D) Table showing the PCR confirmed mutation for the CCM lesions in (A)-(C). 
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Figure 4.5: Pharmacological ROCK inhibition decreases phosphorylation of cofilin 
and MLC2 in a dose-dependent manner. (A) and (B) Phospho-LIMK and phospho-
cofilin are increased in CCM1, -2, and -3 knockdown endothelial cells and 
normalized by small molecule inhibition of ROCK with Fasudil. (C) Western blot 
showing that increased phospho-cofilin in CCM2 knockdown MEECs is decreased 
by Fasudil treatment in a dose-dependent manner. (D) Increasing Fasudil 
concentration decreases elevated phospho-MLC2 in shCCM2 MEECs in a dose-
dependent manner, and overall hyperphosphorylation follows a similar pattern to 
phospho-cofilin. All graphs represent 2 independent experiments, and error bars 
represent SEM. *p<0.05, **p<0.02, ***p<0.001. 
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Figure 4.6: LIMK knockdown and ROCK inhibition rescue tube formation in CCM1, -
2, and -3 knockdown MEECs. (A) and (B) shCCM/LIMK1 endothelial cells were 
created with high levels of knockdown of both proteins. LIMK1 knockdown 
decreases LIMK and cofilin hypersphosphorylation seen with loss of the CCM 
proteins. (C) shCCM cells fail to rearrange into tube-like structures in an in vitro tube 
formation assay. ROCK inhibition with Fasudil and LIMK knockdown rescue tube 
formation to approximately wild type levels. Quantitation represents two independent 
experiments; ***p<0.001. Images are 3x3 montages at 10x magnification, and scale 
bar is 100µM. 
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Figure 4.7: LIMK1 knockdown rescues functional defects in CCM2 knockdown 
endothelial cells. (A) Tube formation is impaired in CCM2 knockdown MEECs. 
shCCM2/shLIMK1 ECs display increased tube formation ability, similar to pLKO.1 
controls. N=3, *p<0.05. (C) Invasion ability is impaired with CCM2 knockdown, but 
rescued with LIMK1 double knockdown. (C) Tube formation time course from live 
imaging. pLKO.1 control cells undergo morphology change by 2 hours and sprouting 
by 4 hours, with nascent tube formation by 6 hours, while CCM2 knockdown cells 
remain mostly rounded and do not form tubes. ROCK inhibition and LIMK1 double 
knockdown rescue tube formation. Scale bar is 50µM. (D and E) The rescue effect of 
LIMK1 knockdown on shCCM2 cells corresponded with decreased phospho-cofilin 
but elevated phospho-MLC2, showing that decreased phospho-cofilin is sufficient to 
rescue tube formation defects. Bands are quantitated relative to pLKO.1 control and 
graphs represent quantitation of 3 independent experiments, *p<0.05, error bars 
represent SEM. 
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Familial Case Mutation 
CCM1 CCM1 c.1363C>T (Common Hispanic 
Mutation) 
CCM2 CCM2 Large Deletion Exons (2-10) 
CCM3 CCM3 c.474 +1G>A (Exon 8 Splice Site) 
 
 
Table 4.1. Mutations in surgically resected CCM lesions obtained from the Angioma 
Alliance used in Figure 3.3. Peripheral blood mononucleocytes from clinically and 
radiographically confirmed familial CCM patients were screened for common CCM 
mutations using PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V. Human endothelial progenitor-derived endothelial cells as a model system 
for Cerebral Cavernous Malformation disease 
 
Introduction 
 Recent findings have shed much light on the pathophysiology of CCM, but are 
limited by the fact that there is currently no robust human cell model system allowing 
for the study of endothelial CCM gene mutations. RNAi for the CCM proteins has 
been helpful in a variety of human and mouse endothelial cell lines, but knockdown 
is not the same as expression of mutant protein. Likewise, CCM GEMMs have been 
very useful, but do faithfully recapitulate the mutations seen in human patients. An 
ideal endothelial cell model system for CCM research would allow efficient RNAi-
mediated knockdown of different genes, proliferate and perform functional assays 
robustly, and most importantly, could be easily isolated from humans for the study of 
familial CCM mutations. Endothelial progenitor-derived endothelial cells (EP-ECs), 
fulfill these parameters. These cells can be isolated from whole blood and proliferate 
robustly. EP-ECs are amenable to infection with lentivirus for efficient knockdown of 
the three CCM proteins and maintain endothelial cell properties such as tube 
formation through at least passages 4 through 12 (188). EP-ECs display 
cobblestone morphology and are strongly positive for Vascular Endothelial Cadherin 
(CD144), Platelet Endothelial Cell Adhesion Molecule-1 (CD31), and Von Willebrand 
Factor, all important endothelial markers (189, 190). They are positive for CD34, a 
progenitor marker, and negative for CD14, a monocyte marker (131). Wild type EP-
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ECs have been characterized in a number of angiogenic assays, including tube 
formation, migration, proliferation, and spheroid sprouting (189, 191). EP-ECs can 
be successfully frozen and stored in liquid nitrogen with negligible affect on growth 
or function. Developing EP-ECs as a model system for CCM could allow for the first 
time the ability to faithfully replicate the pathophysiology of known patient mutations, 
and accurately characterize the biology of CCM genetic heterozygosity in endothelial 
cells. Here, a CCM phenotype is demonstrated in EP-ECs, along with dysregulation 
of small GTPase signaling with loss of CCM1, -2, or -3.  
 
Results 
Characterization of wild type EP-ECs from healthy volunteers 
EP-ECs were isolated from whole blood of volunteer UNC graduate students 
and characterized in order to establish the wild type baseline of EP-EC biology (UNC 
IRB #10-1595). EP-ECs form tube-like capillary structures when incubated on 
Matrigel overnight, a key marker for endothelial cells (Fig. 4.1A). EP-ECs express 
high levels of mRNA for the CCM proteins, with CT values in the low to mid 20s (Fig. 
4.1B). These cells also are positive for PECAM-1 and VE-cadherin, important 
endothelial markers, as well as the progenitor marker CD34 (Fig. 4.1B). They have 
previously been characterized as negative for the monocyte marker CD14. EP-ECs 
are also positive for the uptake of acetylated low-density lipoprotein (LDL), another 
marker characteristic of endothelial cells (Fig. 4.1C). Importantly, message RNA 
knockdown of greater than 80% can be achieved with multiple shRNAs of each CCM 
protein, indicating that EP-ECs are amenable to lentiviral silencing (Fig. 4.1D). 
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CCM1, -2, and -3 knockdown results in angiogenesis assay defects in EP-ECs 
CCM1, -2, or -3 knockdown results in a loss of tube formation ability, an 
assay that measures the ability of endothelial cells to migrate and undergo 
substantial cytoskeletal rearrangement in order to transition from cobblestone 
morphology to flat and elongated tubes. CCM message knockdown leads to 
disrupted tubes with clusters of cuboidal cells (Fig. 4.2A). Addition of the ROCK 
inhibitor Fasudil to the media at a concentration of 10µM resulted in rescue of tube 
formation ability, presumably because of normalization of phosphorylation of 
hyperactive RhoA/ROCK pathway seen with loss of the CCM proteins in other 
endothelial cells (Fig. 4.2A). Tube formation was quantitated by averaging mean 
tube length over multiple experiments. CCM knockdown EP-ECs displayed a 
statistically significant decrease in tube formation, with small molecule ROCK 
inhibition rescuing tube length (Fig. 4.2B). CCM1, -2, and -3 knockdown EP-ECs 
also demonstrated defective invasion ability compared to wild type cells (Fig. 4.3). 
The invasion assay measures the ability of cells to dissolve and move through a thin 
layer of Matrigel, and requires both secretion of matrix metalloproteases and 
substantial cytoskeletal rearrangement to migrate through thin pores. Similarly to 
tube formation, dosing with 10µM Fasudil rescues tube formation in shCCM1 and -2 
EP-ECs, with a weak rescue of shCCM3 EP-ECs (Fig. 4.3). Together, these data 
indicate that loss of the CCM proteins leads to defects in in vitro angiogenesis. 
These defects suggest that CCM knockdown cells have difficulty rearranging the 
actin cytoskeleton compared to wild type cells. Importantly, this data confirms 
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previous observations in mouse and human primary cells, and supports that EP-ECs 
are a robust endothelial cell system for performing CCM research.  
 
Loss of the CCM proteins dysregulates small GTPase signaling in EP-ECs 
Previous work has shown that loss of the CCM proteins leads to increased 
levels of total and active RhoA, presumably through decreased degradation of RhoA 
by the E3 ubiquitin ligase SMURF1. Knockdown of CCM1, -2, and -3 in EP-ECs 
similarly leads to statistically significant increases in total RhoA (Fig. 4.4A). Elevated 
RhoA is consistent with the loss of tube formation and invasion ability seen in CCM 
deficient EP-ECs. Total protein levels of a second small GTPase, Rap1, was also 
found to be significantly elevated with loss of the CCM proteins (Fig. 4.4B). This is 
significant because Rap1 is a master regulator of endothelial permeability, and CCM 
pathophysiology is ultimately believed to result from a loss of vascular integrity in 
endothelial cells. MLC2 and cofilin, important downstream cytoskeletal effectors of 
the RhoA/ROCK pathway, are also dysregulated with loss of the CCM proteins in 
EP-ECs. Phospho-MLC2 is increased in shCCM1, -2, and -3 EP-ECs, indicating 
high ROCK activity and consistent with the cytoskeletal phenotype observed with 
loss of the CCM proteins (Fig. 4.4C). Likewise, phospho-cofilin is increased in 
shCCM EP-ECs, which is consistent with the elevated LIMK signaling we 
demonstrated in mouse endothelial cells (Fig. 4.4D). Together, 
hyperphosphorylation of these pathways leads to increased stress fibers and actin 
accumulation, and loss of normal cytoskeletal rearrangement ability. 
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Discussion 
EP-ECs are a robust primary endothelial cell system that can be isolated from 
the blood of CCM patients, providing a potentially significant tool to understand CCM 
biology in the context of human mutations and not cell lines or mouse models. EP-
ECs display endothelial markers and phenotypes, and can be expanded to large 
numbers from a single blood draw. They also have faithfully recapitulated the 
signaling demonstrated in mouse or human cell lines lacking the CCM proteins, 
adding a novel cell system to the evidence for RhoA/ROCK hyperactivation in CCM. 
If adapted as a model system for CCM, EP-ECs could be useful in a number of 
ways. EP-ECs could be a tool for studying the heterozygous CCM phenotype. CCM 
lesions are believed to develop with loss of heterozygosity when both alleles of 
CCM1, -2 or -3 are mutated. Familial patients inherit one mutant allele, thus EP-ECs 
from familial patients will be heterozygous for a CCM gene mutation. Current 
evidence using graded shRNA knockdown and heterozygous deletion of CCM1 or 
CCM2 by targeted gene knockout in mice suggests a heterozygote phenotype can 
be measured in endothelial cells (142). Given the relatively high frequency of CCM 
mutation carriers in the general populace, it has been suggested that there is a 
selective advantage to CCM heterozygosity, and investigation of this hypothesis 
would improve general understanding of the normal biological role of the CCM 
proteins. 
The ability to isolate primary endothelial cells from patients could also have 
clinical applications. If conditions could be standardized, it is possible that in vitro 
assays such as tube formation or cofilin phosphorylation could be correlated with 
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symptom severity or clinical outcome, providing a prognosis for clinicians and 
patients. As small molecule inhibitors are developed to treat CCM, individualized 
treatment could be achieved by testing the effects on patient EP-ECs. Finally, 
successful isolation of EP-ECs could be used to create induced pluripotent stem 
cells, and even create a library of these lines for therapeutic purposes. Further 
characterization of EP-ECs is still required, but they are a promising model system 
for CCM disease and may play a role in the effort to find a cure. 
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Fig. 5.1: Characterization of EP-ECs from wild type human donors. (A) Wild type EP-
ECs form tube-like capillary structures when incubated on Matrigel overnight. (B) 
EP-ECs are positive for uptake of acetylated LDL, a hallmark of endothelial cells. (C) 
High levels of CCM message knockdown can be achieved with independent 
shRNAs. 
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Fig. 5.2: EP-ECs with high level of shRNA knockdown for the CCM proteins fail to 
form tubes when incubated on Matrigel overnight. (A) EP-ECs lacking CCM1, -2, 
and -3 display a defect in tube formation compared to control cells. Tube formation is 
rescued by ROCK inhibition. (B) Quantitation of mean tube length. N=2, error bars: 
*p<0.05. 
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Fig. 5.3: Knockdown of CCM1, -2, or -3 with shRNA results in decreased invasion 
through Matrigel. Treatment with the ROCK inhibitor Fasudil rescues invasion for 
CCM1 and -2 knockdown, with weak rescue of CCM3. 
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Fig. 5.4: The biochemical signature of loss of the CCM proteins. (A) Total RhoA is 
increased with loss of CCM1, -2, or -3. (B) A second small GTPase, Rap1, is 
increased with loss of the CCM proteins. (C) and (D) Myosin light chain 2 and cofilin, 
two proteins downstream of ROCK, are increased by loss of the CCM proteins. Error 
bars: *p<0.05, **p<0.02. 
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Marker Average CT 
Beta actin 17.7 
CCM1 24.7 
CCM2 22.6 
CCM3 23.3 
PECAM-1 18.0 
VECadherin 18.0 
CD34 23.0 
 
Table 5.1: CCM1, -2, and -3 message is expressed at high levels, along with the 
endothelial markers PECAM-1 and VECadherin and the progenitor marker CD34. 
 
 
 
 
 
VI. Defining the functional domain of Cerebral Cavernous Malformation 3 
through its interactions with phosphatidylinositol-3-4-5 triphosphate 
 
Introduction 
 Cerebral cavernous malformations (CCM) are congenital or sporadic 
vascular disorders of the central nervous system (9, 10, 169). Prevalence ranges 
from 0.5 percent in the general population to 1.5 percent in Hispanics (65, 66, 192). 
Histopathologically, CCM are abnormally large harmatomous vascular lesions 
formed by a single layer of capillary endothelial cells without the support of brain 
parenchyma (9, 193). Ruptured CCM lesions can cause hemorrhagic stroke and are 
often associated with seizures, recurrent headaches, and focal neurological defects 
(9, 10, 42). Three CCM loci have been mapped in humans: 7q21-22 (Krit-1 or 
CCM1), 7p13-15 (OSM or CCM2), and 3q25.2-27 (PDCD10 or CCM3). Mutations in 
these CCM loci cause loss of function of these proteins and result in CCM disease 
(72, 192, 194, 195). 
 CCM3, the smallest of the CCM proteins, is a 25 kilodalton protein 
composed of 212 amino acids. It was originally identified as TF-1 cell apoptosis 
related gene-15 (TFAR15), since it is upregulated with the induction of apoptosis by 
serum withdrawal in TF-1 human premyeloid cells (21, 196). It was subsequently 
renamed PDCD10 (Programmed Cell Death 10) as it was thought to be involved in 
apoptotic responses (21, 196). CCM3 is the third and latest CCM gene identified 
(21). The N-terminal region of CCM3, which in some CCM patients is the site of an 
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in-frame deletion of an entire exon encoding from L33 to K50, was found to be the 
binding site for the oxidant stress response serine/threonine kinase 25 (STK25) and 
the mammalian Ste20-like kinase 4 (MST4) (197). Similar to earlier observations, 
CCM3 was found to function in apoptotic pathways since overexpression of CCM3 
induces apoptosis through the caspase 3 pathway (79). Furthermore, CCM3 may be 
regulated through phosphorylation and dephosphorylation, since it can be 
phosphorylated by STK25 and dephosphorylated by binding to the phosphatase 
domain of Fas-associated phosphatase-1 (173). Recently, we showed that all three 
CCM proteins form a complex in the cell and that CCM3 binds directly to CCM2 
independently of the CCM2-CCM1 interaction (69). We also showed that CCM3 
binds to both phosphatidylinositol bis- or tris-phosphates, but seems to have the 
highest affinity to phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) (69). 
However, it is not known which part of CCM3 binds to PtdIns(3,4,5)P3 or CCM2 
because there is currently no structural data available for CCM3. Creating a 
structural model of CCM3 is, therefore, a critical first step to provide insight into the 
CCM3 structure-function relationship. The interaction of CCM3 and PtdIns(3,4,5)P3 
suggests that CCM3 may function in concert with phosphatidylinositol-3-kinase 
(PI3K), the enzyme that catalyzes the formation of PtdIns(3,4,5)P3 at the plasma 
membrane (198). PI3K activation by growth factors including vascular endothelial 
growth factor (VEGF) is known to be crucial in angiogenesis. Thus, a relationship 
between CCM3 and PI3K would be evidence that CCM development may result 
from dysregulation in the PI3K pathway through CCM3-PtdIns(3,4,5)P3 interaction. 
In this study we attempted to define the functional domain of CCM3 that is important 
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in PtdIns(3,4,5)P3 binding by using molecular modeling combined with site-directed 
mutagenesis. 
 Homology modeling allows for identification of critical amino acid 
residues for protein-protein interaction and protein-ligand interaction (199). The 
usefulness of homology is inversely dependent on the evolutionary distance 
between the target and templates (200). The structural conservation between the 
target and template, as well as the correctness of the template alignment, are 
among the most important factors in generating homology models. Generating a 
homology model for CCM3 is therefore challenging because of the low structural 
conservation with available templates and low sequence identity between CCM3 and 
the templates (200-202). Our homology models and biophysical data predict that 
CCM3 is likely a dimeric six-helical protein composed of two trihelical heptad-repeat 
structures. We identified the amphipathic helix and Lys residues essential for CCM3-
PtdIns(3,4,5)P3 and CCM3-CCM2 interaction. Finally, we demonstrated that using 
membrane-bound constitutively active PI3K (p110-CAAX), the wild type CCM3 co-
localizes with the p110-CAAX mostly at the plasma membrane, while the mutants 
lacking Lys residues remain in the cytoplasm.    
 
Results 
Threading analysis and homology modeling of CCM3 
Threading analysis and homology modeling was performed by Dr. Sompop 
Bencharit as part a collaboration with the Johnson lab. It should be noted that 
subsequent to the publication of this work, CCM3 was successfully crystalized to a 
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2.5 Ångstrom resolution by Li et al. (80). Obviously, modeling will never be as 
thorough as empirical structural studies, but some predictions from this modeling 
were shown to be correct. Most importantly, Dr. Bencharit’s model predicted that 
CCM3 was mostly composed of alpha helices, and that it homoderized and existed 
in solution as a homodimer. The crystal structure confirmed the alpha helical 
secondary structures of the protein, although it was demonstrated to possess 9 
rather than the predicted 6. CCM3 was also shown to exist both in solution and in 
vivo as a homodimer. Several predictions turned out to not be accurate, including 
the lack of a hinge region between the N and C-terminals of the protein, and the 
location of the dimerization domain. 
The structure of CCM3 was first examined using 3D-Jury to generate meta-
predictions for CCM3 (203). Unlike CCM1 or CCM2, which are large scaffolding 
proteins composed of multiple functional domains, CCM3 seems to have a compact 
single domain structure. The structures predicted by threading analysis to be most 
similar to CCM3 include a six-helical bundle protein of no known function (1xwm), a 
five-helical bundle structure of vinculin (1rke), a four-helical bundle structure of the 
FAT domain of focal adhesion kinase-FAK (1pv3), and a four-helical bundle 
structure of the SNARE complex (1sfc) (Table 6.1). Most of these helical bundle 
proteins, similarly to CCM3, are highly conserved throughout evolution. Like CCM1 
and CCM2, these helical bundle proteins also function mainly in protein localization 
to the cytoskeleton and cellular membranes (204-206). Based on this threading 
analysis, CCM3 is likely to be a helical bundle protein composed of four to six 
helices. The compact structure of CCM3 is uniquely distinct from CCM1 and CCM2 
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and suggests that CCM3 may be an adaptor protein. 
To further define the functional domain of CCM3, multi-target modeling was 
used to generate a three dimensional model (151-153). The model of CCM3 shows 
a double heptad-repeat-hairpin structure and the potential interactive surfaces of 
CCM3. The overall theoretical structure of CCM3 is an α-helical structure with over 
68% of the amino acids in α-helical conformations (Fig. 6.1 A-B). This structure is 
composed of a six-helix bundle formed by two three-helix bundles connected by a 
15-residue loop. The N-terminal three-helix bundle is composed of α1, α2, and α3, 
while the C-terminal three-helix bundle is composed of α4, α5, and α6. The interface 
between these two three-helix bundles forms a hydrophobic core, which is mediated 
mainly through hydrophobic residues located in α1- α4 and α3- α6. These two three-
helix bundles are structural repeats known as heptad-repeats, a common random 
hydrophobic/hydrophilic repeat in coiled-coil structures (207-209) (Fig. 6.2 A-B). The 
superposition of the two structural repeats of the three-helix bundle, α1- α3 with α4- 
α6, results in a root mean squared deviation of about 5 Å over 85 equivalent Cα 
atoms (Fig. 6.2 A-B). The major difference between these two repeats is that α1 is 
about 13 amino acids longer than α4. The other two helices, of the helical repeats 
α2/α4 and α3/α6, can be superimposed. Similar to the PhoU structures, 
superposition of the two repeats suggested that the protein sequences in these two 
repeats might be evolutionarily related (210) (Fig. 6.2 A-B). Based on 
superimposition of all generated models, the C-terminal portion of the homology 
model appears to be more correct, while the N-terminal portion is less certain. The 
predicted ligand-binding site is likely to be in the very end of the C-terminal portion. 
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We therefore focused on the use of the homology model and ligand interaction in the 
C-terminal portion and did not attempt to predict other ligand interactions in the N-
terminal portion. 
CCM3 contains an unusually large number of highly flexible sidechains for a 
small protein: 21 lysine and 21 glutamate residues out of 212 total amino acids. 
Lysine and glutamate residue clusters are known to exhibit a highly variable surface 
due to flexible conformations (211-214). This allows for structural flexibility of the 
protein molecule that, in combination with hydrophobic areas, is often present in an 
interactive surface of a ligand or protein binding partner. The lysine residues in 
CCM3 are conserved and located among conserved hydrophobic residues, in 
particular the C-terminal region (Fig. 6.1 A, 6.2 C). Our CCM3 theoretical model 
suggests that this C-terminal region of CCM3 may form an amphipathic helix that 
potentially binds to membrane phospholipids. Note that the majority of proteins with 
an amphipathic helix capable of binding to phospholipids often have lysine residues 
predominantly interspersed with hydrophobic residues, for example, the epsin ENTH 
domain (Protein Data Bank (PDB) code 1H0A), and the AP180/CALM ANTH domain 
(PDB code 1HFA) (215-217). In the case of CCM3, almost 10% of its amino acid 
content consists of scattered lysine residues. This distribution of lysine residues is 
seen in protein structures that interact with inositolphosphate ligands, including 
Drosophila melanogaster amphiphysin (PDB code 1URU), endophilin-A1 BAR 
domain (PDB code 1ZWW), CIP4 (Cdc42-interacting protein-4), F-BAR domain 
(PDB code 2EFK), and the IMD domain from IRSp53/missing-in-metastasis (PDB 
code 1Y2O) (218-221). Lysine residues inside the bend of the cytoplasmic 
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membrane indicate that the protein is sensing or stabilizing a highly curved 
membrane (217). There are five conserved lysine residues in α5 and a flexible loop 
that connects this helix with the last helix, α6, including K169, K172, K179, K183, 
and K186 (Fig 6.2C). Surface potential analysis of the theoretical structure showed 
that these lysine residues form a cluster of positive charges interspersed with the 
hydrophobic residues (Fig 6.3 A-C). These observations, in combination with our 
previous data showing that CCM3 selectively binds to phosphatidylinostiol bis- and 
trisphosphates, but binds PtdIns(3,4,5)P3 with strongest affinity, led us to 
hypothesize that this area could be a potential amphipathic helix that may play a role 
in PtdIns(3,4,5)P3 binding (222). 
 
Defining the PtdIns(3,4,5)P3 binding site of CCM3  
To determine whether the five lysines forming an amphipathic helix in our 
theoretical structure are important in PtdIns(3,4,5)P3 binding, we generated three 
mutants designed to eliminate important PtdIns(3,4,5)P3 binding lysine residues with 
two, three and five lysine-to-alanine mutations; ∆2KA (K169A, and K172A), ∆3KA 
K179A, K183A and K186A), ∆5KA (K169A, K172A, K179A, K183A, and K186A). 
The mutations in ∆2KA are located in the N-terminal portion of the amphipathic helix 
(α5), while the ∆3KA ones are in the C-terminal portion of the helix. The ∆5KA 
mutations would cover all possible lysines in the amphipathic helix. We expressed 
these recombinant mutant proteins along with wild type CCM3 with an N-terminal 
6xHis-tag in bacteria as previously described (69). We investigated the phospholipid 
binding potential of the CCM3 recombinant proteins using Membrane Lipid Array 
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and PIP-Arrays (Echelon, USA). 
In the Membrane Lipid Array, wild type CCM3 binds weakly but specifically to 
phosphoserine (Fig. 6.4A). However, in PIP-Arrays, wild type CCM3 selectively 
binds PtdIns(3,4,5)P3 with high affinity, and the phosphatidyl bisphosphates 
phosphatidylinositol 3,4 bisphophate (PtdIns(3,4)P2), phosphatidylinositol 3,5 
bisphophate (PtdIns(3,5)P2), and phosphatidylinositol 4,5 bisphophate 
(PtdIns(4,5)P2) with moderate but lower affinity (Fig. 6.4B-C). We further screened 
for important lysine residues that are essential for PtdIns(3,4,5)P3 binding using 
mutant proteins. The ∆5KA mutation completely abolishes PtdIns(3,4,5)P3 and 
phosphatidylinositol bisphosphate binding, while the ∆2KA and ∆3KA mutants 
maintain similar phosphatidylinositol bisphosphates and PtdIns(3,4,5)P3 binding 
selectivity (Fig. 6.4A-C). Interestingly, the ∆3KA seems to have lower affinity to 
phosphatidylinostol bisphosphates than the wild type and the ∆2KA. These results 
suggest that all five lysine residues play a critical role in PtdIns(3,4,5)P3 binding. 
However, there is some redundancy in the system and two to three lysines are 
sufficient for specific phosphatidylinositol bis- and tris-phosphate binding. It would be 
of interest to measure circular dichroism with each ∆KA mutant in order to determine 
whether the apparent increase in lipid-binding affinity with the ∆2KA mutant is due to 
true differential stability between the wild type and ∆KA mutants or simply an artifact 
of concentration differences of the proteins. 
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CCM2 interaction with ∆5KA, a CCM3 mutant lacking PtdIns(3,4,5)P3 binding 
residues 
CCM2 interacts with CCM1 through a canonical PTB domain/NPXY motif 
interaction. Recently, we demonstrated that CCM3 interacts with the CCM2-CCM1 
complex by interacting with CCM2 (69). However, the mode of CCM2-CCM3 
interaction is not known. The phosphatidylinositol bis- and tris-phosphate binding 
study indicated that there are five lysines located on the area of the α5 amphipathic 
helix that function as a PtdIns(3,4,5)P3 binding site (Fig. 6.2A,C). Based on our 
model, these five lysines reside in a surface exposure. For a relatively small protein 
like CCM3, we expected that there may be redundancy in PtdIns(3,4,5)P3 and 
protein-protein interaction. We therefore further investigated if these lysines in the 
amphipathic helix (α5) are also involved in interactions with CCM2. Recombinant 
purified wild type and ∆5KA CCM3 coupled to sepharose beads were used to pull-
down FLAG-tagged overexpressed CCM2 and CCM1 (Fig. 6.4C). Interestingly, 
these pull-down experiments showed that the mutant fails to interact with CCM2. 
These data suggests that the five lysine residues in this C-terminal region of CCM3 
are not only important in CCM3-PtdIns(3,4,5)P3 interaction, but also important in 
CCM3-CCM2 interaction.  
 
Secondary and tertiary structures of CCM3 
To ensure that the mutation of lysines in ∆5KA does not alter the overall 
protein structure, we further examined the secondary and tertiary structures of the 
wild type and ∆5KA mutant using purified recombinant proteins. Consistent with the 
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modeling data, the circular dichroism (CD) spectra of the wild type and ∆5KA 
appears to be of α-helical proteins. While the CD spectra of the wild type and ∆5KA 
mutant were almost identical, the Tm of the wild type is about 7 °C lower than the 
one of the ∆5KA (Fig. 6.5A-B). These results suggest that while the ∆5KA maintains 
similar secondary structure to the wild type, it has lower molecular stability, perhaps 
as a result of five K-to-A mutations. In addition to examining the secondary structure, 
we used HPLC size-exclusion chromatography coupled with multi-angle laser light 
scattering (SEC-MALS) to determine the native molecular weights of the wild type 
and ∆5KA CCM3 proteins (Table 6.2). The results showed that both proteins are 
slightly larger than 50 KDa and therefore form a dimeric complex in solution. This 
dimeric form is the only species found in both wild type and ∆5KA recombinant 
protein. The dimeric interface is therefore mutually exclusive from the phospholipid 
and CCM2 binding surface. The surface potential model of CCM3 showed a highly 
negative charge area in the first trihelical heptad repeat and a highly positive charge 
area in the second trihelical heptad repeat (Fig. 6.3D). The optimal docking area 
method indicates that these areas may play a role in the dimerization of CCM3 
(156). 
 
Cellular co-localization of CCM3 and membrane-bound constitutively-active 
phospholinositol-3-kinase (p110-CAAX) 
The fact that CCM3 seems to have the highest affinity with PtdIns(3,4,5)P3 
led us to believe that CCM3 may function with phospholinositol-3-kinase (PI3K). 
PI3K is a master kinase that catalyzes the phosphorylation of PtdIns(4,5)P2 to 
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produce PtdIns(3,4,5)P3. PI3K catalyzes PtdIns(3,4,5)P3 formation upon activation 
by growth factors such as VEGF (198). We used the catalytic subunit of PI3K 
(lacking a regulatory domain) with a COOH-terminal plasma membrane targeting 
sequence to produce a PI3K construct that is constitutively active (p110-CAAX) 
(223-225). When wild type CCM3, ∆5KA, and p110-CAAX were co-transfected, wild 
type CCM3 and p110-CAAX were co-localized, while the ∆5KA was not (Fig 6.6). 
This experiment confirms our biophysical data and suggests that CCM3 binds to 
PtdIns(3,4,5)P3 and may function in the PI3K signaling pathway. 
 
Discussion 
CCM is a unique example of a genetic disorder that results from the 
dysfunction of three non-catalytic scaffold proteins. CCM1-CCM2-CCM3 forms a 
ternary complex in the cell and CCM lesions appear to result from a loss of integrity 
of this complex. While CCM1 and CCM2 proteins both have known structural 
domains and functionally link to several important signaling pathways, including 
integrin signaling, the p38 MAP kinase pathway, and RhoA-Rho kinase regulation, 
CCM3 lacks known structural domains. CCM3 was thought to relate to apoptosis; 
however, there is no clear apoptotic pathway known. Defining a functional domain of 
CCM3 is therefore important in learning how this protein functions and contributes to 
CCM development. Combining molecular modeling and site-directed mutagenesis, it 
appears that CCM3 is a six helical bundle protein composed of a two heptad repeat, 
and α5 is an important amphipathic helix housing five lysine residues essential for 
PtdIns(3,4,5)P3 binding. Unlike phosphatidylinositol specific domains, for instance 
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C1, PH, PX and FYVE, amphipathic helices often only demonstrate high specificity 
to certain phosphatidylinositol molecules under specific circumstances, such as 
when the membrane area possesses a highly curved region (217). We speculate 
that this may be the case for CCM3 since there seem to be multiple lysine residues 
beyond the amphipathic helix similar to some phosphatidylinositol binding proteins 
that use these outside amphipathic helix lysine residues to interact with the curved 
membrane region (219, 220, 222). We further show that the ∆5KA, a mutant lacking 
these five important K residues, does not bind to PtdIns(3,4,5)P3 in vitro. While the 
wild type and ∆5KA both appear to have the same helical secondary/tertiary 
structure, and are dimeric in solution, the ∆5KA does not bind CCM2. In addition, 
when wild type CCM3 and ∆5KA are co-expressed with p110-CAAX, a membrane-
bound/constitutively active PI3K, wild type is co-localized with p110-CAAX at the 
plasma membrane. However, ∆5KA stays in the cytoplasm. The results suggest that 
CCM3 may function with PI3K.  
A recent study shows that CCM3 functions in VEGF-dependent translocation 
of vascular endothelial growth factor receptor 2 (VEGFR2) and further, suggests that 
the C-terminal portion of CCM3 is important in CCM3-VEGFR2 interaction (66). 
VEGF is an upstream regulator of PI3K. It is therefore plausible that CCM3 may play 
a role in VEGF-PI3K signaling. Interestingly, colocalization of CCM3 and PI3K in our 
study is almost identical to the colocalization of CCM3 and VEGFR2 (34). It is 
possible that this co-localization is a result of CCM3 and VEGFR2 interactions. It 
was shown that CCM3 interacts with VEGFR2 through its C-terminal region. This 
region overlaps with the PtdIns(3,4,5)P3 binding where we located the five 
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PtdIns(3,4,5)P3 binding lysines. These lysines are also important in CCM3-CCM2 
interaction. Furthermore, genetic studies demonstrate that this region is predisposed 
to frameshift mutations that often cause early termination of the protein resulting in 
CCM (21). We therefore speculate that CCM3-CCM2 and CCM3-VEGFR2 
interactions may be regulated by the availability of PtdIns(3,4,5)P3 generated by 
PI3K. 
Based on our findings and recent studies, we composed a signaling model for 
CCM3 (Fig 6.7). We propose that CCM3 functions closely with VEGFR2 and PI3K. 
Upon activation of VEGFR2 by VEGF, VEGFR2 binds to dimeric CCM3, 
translocates to the membrane, and becomes activated. As a result of VEGFR2 
activation, PI3K is activated and favors the catalysis of PtdIns(3,4)P2 or PIP2 to 
PtdIns(3,4,5)P3 or PIP3 (Fig 6.7). PtdIns(3,4,5)P3 goes on to bind CCM3 and AKT. 
There may be an equilibrium between CCM3-PtdIns(3,4,5)P3 and CCM3-
CCM2/CCM1, as well as a equilibrium between CCM3-PtdIns(3,4,5)P3 and AKT-
PtdIns(3,4,5)P3. PtdIns(3,4,5)P3 and CCM2 seem to have the same interactive site 
on the CCM3 dimer, and it is possible that VEGFR2 may also share the same 
binding site. It is therefore plausible that CCM3 may regulate the function of these 
three important signaling molecules at the same time using simple chemical 
equilibrium. 
We propose that one mechanism of CCM development may result from the 
dysregulation of the VEGF/PI3K signaling pathway through CCM3- PtdIns(3,4,5)P3 
interaction. Future experiments will need to be completed to define the role of CCM3 
in PI3K signaling. PI3K can be activated by several growth factors, including VEGF. 
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Characterizing the role of CCM3 during PI3K activation by VEGF, as well as 
downstream effectors such as AKT1, will be important in understanding CCM 
development and how we may treat this condition by modulating the activity of these 
kinases. Linking the role of CCM3 in the VEGF/PI3K pathway to other CCM proteins 
will elucidate the individual roles of CCM proteins, as well as the CCM protein 
complex. We recently showed that CCM2 plays a role in regulating the degradation 
of the small GTPase RhoA and that the CCM endothelial phenotype can be rescued 
with knockdown or inhibitors of ROCK-RhoA effectors (86). Interestingly, activation 
of PI3K can also increase RhoA activation (226). Further experiments will also be 
needed to determine if CCM3 functions in concert with CCM2 and CCM1 in signaling 
the regulation of RhoA and PI3K. 
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Figure 6.1: (A) Multiple sequence alignment of mouse, human, and zebra fish CCM3 
showing a highly conserved primary structure. (B) A three-dimensional model for 
CCM3 shows a double heptad-repeat-hairpin structure. 
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Figure 6.2: (A) Sequence alignment of the N-terminal and the C-terminal three-helix 
bundles. (B) Superimposition of the N-terminal and C-terminal three-helix bundles 
shows that these two heptad-repeat-hairpin structures are related in the three 
dimensional structures. (C) A diagram and primary sequence of the proposed 
amphipathic helix and the PIP binding site. 
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Figure 6.3: (A) Ribbon model of CCM3 showing the proposed PIP binding Lys 
residues. (B) A surface-potential model of CCM3 showing the surface positive 
potential charge area (in blue) and negative potential charge area (in red). (C) 
Superimposition of the ribbon model and the surface potential model. Note the 
proposed PIP binding Lys residues. (D) Superimposition of the ribbon model and the 
surface-potential model shows the potential dimeric interface. (Note that these 
dimeric interaction surfaces are mutually exclusive to the PIP binding site.) 
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Figure 6.4: (A) The Membrane Lipid Array shows that CCM3 binds exclusively to 
phosphotidylserine with weak binding. (B) The PIP Arrays shows the relative PIP 
binding affinity for the wild type and three mutant CCM3 proteins. (C) Pull-down 
experiments, using the recombinant purified wild type and ∆5KA CCM3 coupled to 
sepharose beads to pull-down flag-tagged overexpressed CCM2 and CCM1, shows 
that only the wild type binds to CCM2-CCM1 complex. 
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Figure 6.5: (A) Circular dichroism spectra of wild type and ∆5KA CCM3 shows 
identical CD spectra. (B) Fraction denaturation experiments show the lower Tm of 
∆5KA compared to the wild type. 
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Figure 6.6: Overexpression of the wild type and ∆5KA CCM3 together with p110-
CAAX shows that the wild type and p110-CAAX colocalized in the cytoplasmic 
membrane while the ∆5KA stays only in the cytoplasm. (A) Wild type CCM3 in 
Mcherry. (B) ∆5KA in CFP. (C) p110-CAAX in FITC (D) A composite picture of wild 
type (Mcherry) and p110-CAAX (FITC). (E) A composite picture of ∆5KA (CFP) and 
p110-CAAX (FITC). (F) A composite picture of wild type (Mcherry) and ∆5KA (CFP). 
(G) A composite picture of wild type (Mcherry), p110-CAAX (FITC), and ∆5KA 
(CFP). (H) A composite picture of ∆5KA (CFP) and p110-CAAX (FITC), a light cyan 
mask was used to enhance the visualization of ∆5KA localization. 
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Figure 6.7: Proposed CCM3 signaling model. 
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Table 6.1: Threading analysis using 3D-Jury.  
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Table 6.2: Determination of quaternary structure of wild type and mutant ∆5KA 
CCM3 in solution using size exclusion chromatography/multi angle laser light 
scattering. 
 
 
 
 
 
 
 
 
 
 
VII. The molecular mechanism of CCM pathophysiology: E3 ubiquitin ligase 
dysregulation and accompanying dysregulation of the kinome 
 
Introduction 
 Despite numerous advances leading to a better understanding of the 
signaling pathways regulated by CCM1, -2, and -3, a molecular mechanism of the 
disease continues to elude us. We and others have demonstrated that loss of the 
three CCM proteins leads to increased total and active RhoA, a small GTPase that is 
a master regulator of the actin cytoskeleton (78, 86, 142). Crose et al. showed that 
PTB domain of CCM2 binds the HECT domain of the E3 ubiquitin ligase SMURF1 
and localizes it to near the plasma membrane where it serves to degrade RhoA (78). 
The role of GEFs, GAPs, and GDIs in RhoA activity regulation has been well 
characterized, but it has also become clear that spatial and temporal regulation of 
RhoA can be controlled by E3 ubiquitin ligases (148). Degradation of RhoA is 
achieved through ubiquitination catalyzed by two E3 ligases: SMURF1 and Cullin3. 
SMURF1 is a member of the HECT domain family of E3 ligases, possessing a C2-
WW-HECT domain architecture with the HECT domain catalyzing with E3 ligase 
activity (148). In addition to other substrates, SMURF1 targets RhoA for 
ubiquitination, leading to its degradation. Because RhoA is a regulator of cell shape, 
polarity, cell-cell contacts, and motility, SMURF1 ultimately regulates a number of 
important cellular processes (227). SMURF1 is thought to preferentially target active 
RhoA at membrane protrusions, thus influencing cell polarity and migration, two 
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phenotypes thought to be dysregulated with loss of the CCM proteins (228). 
Localized degradation prevents reactivation of RhoA by Rho GEFs, therefore 
removing the protein from the rapid on/off cycling that can occur with GEFs and 
GAPs. Interestingly, it does not appear that total RhoA levels change significantly 
when SMURF1 is knocked down, suggesting that SMURF1 regulates the 
degradation of RhoA at sights of active membrane protrusion and not general RhoA 
degradation within the cell (227). The role of SMURF1 in CCM pathophysiology 
needs further investigation, especially in light of the fact that loss of CCM1 and 
CCM3 lead to indistinguishable increases in active RhoA, yet do not bind SMURF1. 
 The association between loss of the CCM proteins and increased active 
RhoA is clear, but the molecular consequences of RhoA dysregulation, as well as 
the rest of the CCM regulatory network, are mostly unknown. In order to address 
these questions in an unbiased way, we used a technology developed by the 
Johnson lab, MIB-MS: multiplexed inhibitor beads coupled with chemical proteomics. 
In this technique, pan-kinase inhibitors are covalently attached to beads and cell 
lysates are flowed through the column, leading to kinase capture that is a function of 
kinase activation, expression, and intrinsic affinity for the inhibitors (159). The 
response of the kinome to protein knockdown or drug treatment can be measured in 
a robust and highly reproducible way, allowing for a broad view of the effects of 
CCM knockdown and ROCK inhibition in endothelial cells. Furthermore, MIB-MS 
allows us to compare the effects of loss of CCM1, -2, or -3, therefore assisting in 
determining the critical question of which pathways are shared and which are 
different between the CCM proteins. 
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Results 
SMURF1 knockdown phenocopies CCM knockdown 
 We hypothesize that CCM2 functions to regulate RhoA activity through 
regulation of SMURF1. Increased active RhoA is associated with increased actin 
stress fibers in endothelial cells, a phenotype that is also seen with loss of CCM1, -2, 
or -3. We generated stable shRNA knockdown SMURF1 HUVECs in order to test 
whether they would resemble the CCM phenotype. While pLKO.1 control endothelial 
cells display a mainly cortical pattern of actin, knockdown of SMURF1 leads to 
increased stress fibers throughout the cell, similar to what is seen with CCM2 
knockdown (Fig. 7.1A). Chemical inhibition of SMURF1 through treatment with the 
neddylation inhibitor MLN4924 also resulted in increased stress fibers, although to a 
lesser extent than shRNA knockdown (Fig. 7.1A). It is unsurprising that chemical 
inhibition of SMURF1 activity is less effective than knockdown of the protein. Stress 
fiber formation is consistent with RhoA hyperactivity, and more specifically, the 
phosphorylation of MLC2. Indeed, knockdown of SMURF1 using several shRNAs 
results in increased phospho-MLC2, providing a biochemical mechanism for the 
increased stress fibers seen in these cells (Fig. 7.1B).  
CCM knockdown cells display defects in several in vitro angiogenesis assays, 
including capillary like tube formation and invasion through Matrigel. In order to 
determine whether SMURF1 knockdown has a similar effect, shSMURF1 HUVECs 
were incubated overnight on Matrigel and tube formation ability was assessed. 
SMURF1 knockdown resulted in a loss of tube formation, similar to shCCM2 cells 
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(Fig. 7.2). Chemical inhibition of SMURF1 activity leads to a modest decrease in 
tube formation. Significantly, treatment with 10µM of the ROCK inhibitor Fasudil 
rescued tube formation in SMURF1 knockdown cells; similar to the effect ROCK 
inhibition has on shCCM2 HUVECs (Fig. 7.2). This supports the importance of the 
role of SMURF1 in the dysregulation caused by loss of the CCM proteins and the 
CCM2-SMURF1-RhoA-ROCK pathway. Since SMURF2 is highly homologous to 
SMURF1 and may bind CCM2 via a similar PTB-HECT domain interaction, we also 
performed tube formation with shSMURF2 HUVECs. SMURF2 knockdown also lead 
to a loss of tube formation ability, but unlike SMURF1 knockdown, was not rescued 
by ROCK inhibition (Fig. 7.3A). This data is interesting because it appears that loss 
of either SMURF E3 ligase is sufficient to cause loss of tube formation in endothelial 
cells, yet only SMURF1 knockdown is rescued with ROCK inhibition, supporting the 
role of SMURF1 in the CCM pathway. 
 
Loss of CCM2 substantially affects the kinome in endothelial cells 
 MIB-MS was performed in collaboration with Bryan Richardson, and run by 
Rachel Reuther, both of the Johnson lab. MIB-MS was performed on CCM2 
knockdown HUVECs in order to expand our knowledge of the CCM signaling 
network in an unbiased way. Given that the CCM proteins lack enzymatic activity 
and relatively few pathways have been defined for them, we were surprised at the 
significant effects loss of CCM2 had on the kinome (Fig. 7.4). To our knowledge, this 
is the first time MIB-MS has been performed in endothelial cells, and certainly in the 
context of CCM. Importantly, MIB-MS validates our findings that ROCK and LIMK 
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activity is increased with CCM2 knockdown (Fig. 7.5). Additionally, the SRC family 
kinases, including Lyn and SRC are up in CCM2 knockdown cells. SRC has been 
shown to affect angiogenesis through the VEGF pathway, although the exact 
significance of this data is unclear.  
 Interestingly, several kinases critical to angiogenesis are highly decreased, a 
profile that is consistent with the vascular defects seen with loss of the CCM 
proteins. The angiopoietin receptor TIE-2 is strongly decreased, as well as the non-
receptor tyrosine kinase BMX (Fig. 7.4). Loss of function mutations in TIE-2 have 
been linked to multiple genetic variants of venous malformations (229). This is 
especially significant because CCM is itself a venous malformation. Loss of BMX 
has been implicated in defects in endothelial cell migration and tube formation in 
vitro, therefore phenocopying loss of the CCM proteins (230). It is unclear at this 
point what the contribution of these two pro-angiogenic kinases are to CCM 
phenotype observed in vitro. 
 While MIB-MS has been demonstrated to be a highly robust technique, 
validation by Western blotting is still important to check protein level and activity. The 
lysates used for MIB-MS displayed increased total RhoA, and high levels of protein 
knockdown of CCM2 in shCCM2 HUVECs (Fig. 7.5A and B). Two significant hits 
were also validated. MIB-MS indicated a decrease in activity/expression of the 
angiopoietin receptor TIE-2 in CCM2 knockdown HUVECs, and indeed shCCM2 
cells display an almost complete loss of TIE-2 (Fig. 7.5C). MIB-MS also showed an 
increase in TGFβ2 receptor, so we probed the lysates for SMAD phosphorylation. 
Surprisingly, there was a significant decrease in phosphorylation of SMAD3, with no 
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corresponding decrease in total SMAD3 (Fig. 7.5D). The finding that phospho-
SMAD3 is lost with CCM2 knockdown suggests that CCM2 may be affecting 
transcription, possibly through CCM1-CCM2 nuclear shuttling. This data should be 
further investigated by performing RNA-seq on CCM2 knockdown cells. Together, 
this data shows the importance of CCM2 in endothelial cells, and the surprising 
extent of the CCM2 signaling network. 
 
Discussion 
 Despite years of work, the molecular mechanism of CCM disease remains 
elusive. The finding that loss of SMURF1 phenocopies loss of the CCM proteins and 
that the phenotype can be reversed with ROCK inhibition is significant because it 
supports the molecular mechanism that CCM2 regulates RhoA activity by controlling 
SMURF1. The fact that SMURF2 is not rescued by ROCK inhibition speaks to the 
yet undefined specificity of CCM2 for the highly homologous SMURF1. The 
indistinguishable angiogenesis phenotypes and increased RhoA activation seen with 
loss of CCM1, -2, and -3 point to dysregulation of a common pathway, but there is 
currently no data linking CCM1 and -3 to SMURF1. Our data indicates that CCM1 
functions to regulate the subcellular localization of CCM2, providing a link to the 
CCM2-RhoA pathway. CCM3 may function similarly, in that its presence in the 
ternary CCM complex is necessary to the function of CCM2 to properly regulate 
degradation of RhoA. Or, perhaps CCM3 functions in a separate pathway, as 
proposed by several others in the field (80, 231). However, our data strongly 
suggests that CCM3 functions in a similar pathway to CCM1 and -2. Regardless, it is 
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unsurprising that the three CCM proteins have separate functions in the cell, in 
addition to a shared common pathway. 
 MIB-MS allows for the first time the ability to observe activation and 
expression of the kinome in an unbiased way. This technique validates our earlier 
findings about CCM regulation of ROCK-LIMK hyperactivation, and by 
demonstrating loss of the critical angiogenesis regulators TIE-2 and BMX provides 
new insight to possible mechanisms for development of CCM pathophysiology. MIB-
MS also shows the importance of CCM2 to the normal endothelial cell kinome. It is 
unclear what the relative contribution of CCM2 versus dysregulation of RhoA is to 
the kinome profile. Clearly, RhoA hyperactivation and subsequent ROCK 
hyperactivity could lead to changes in the kinome or kinome reprogramming. It is 
also possible that CCM2 directly regulates kinases previously unknown to the CCM 
signaling pathway, likely through binding with its PTB domain. Overall, the changes 
in kinase activity observed are most likely multi-factorial; a combination of small 
GTPase hyperactivity, dysregulated SMURF function, and altered spatio-temporal 
control of signaling controlled by the CCM proteins. Future work should profile 
CCM1 and -3 knockdown cells, in order to discover both common and diverse 
molecular pathways. It would be unsurprising if the different CCM proteins had 
different MIB-MS signatures, yet one would also expect certain commonalities. 
Perhaps by comparing the kinome profile of the three proteins better insight could be 
gained to the molecular pathways responsible for CCM pathophysiology. Future 
work should also look at the effect of drug treatment such as ROCK inhibition or 
Simvastatin treatment on CCM knockdown cells. The kinome profile allows for 
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rational treatment design, and in the future could be used to ascertain the kinase 
profile of patient derived endothelial cells. Furthermore, previous work by Duncan et 
al. showed that significant kinome reprogramming occurs in cancer cells in response 
to small molecule inhibition or chemotherapy (159). When testing therapeutics such 
as ROCK inhibitors for CCM, MIB-MS should be used to determine whether kinases 
dysregulated by loss of CCM proteins reprogram or escape drug treatment. MIB-MS 
could also be a useful tool for profiling the kinome of endothelial progenitor-derived 
endothelial cells from CCM patients. It would be interesting to compare the effects of 
different patient mutations on the kinome and be able rule out the possible 
background effects from the viral infection response that can accompany lentiviral 
shRNA knockdown. Finally, MIB-MS could be used to move CCM research beyond 
endothelial cells. The CCM heterozygous kinome could be profiled, perhaps 
shedding light onto the role of the CCM proteins in both normal and dysregulated 
human physiology, including the immune system and neoplasia. 
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Figure 7.1: SMURF1 knockdown phenocopies CCM2 knockdown in stress fibers. (A) 
Actin (phalloidin) and DAPI staining of HUVECs treated with empty vector virus, 
10µM MLN compound, or CCM2 or SMURF1 knockdown by shRNA. MLN and 
SMURF1 knockdown cells display increased stress fibers compared to pLKO.1 
control, resembling the phenotype of CCM2 knockdown endothelial cells. (B) 
SMURF1 knockdown results in increased phosphorylation of myosin light chain 2, 
consistent with the increased stress fibers observed in (A). 
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Figure 7.2: SMURF1 knockdown phenocopies loss of CCM2 in a tube formation 
assay. Both are rescued by treatment with 10µM Fasudil, a ROCK inhibitor. 
Chemical inhibition of E3 ubiquitin ligases through the neddylation inhibitor 
MLN4924 resulted in mildly decreased tube formation.  
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Figure 7.3: SMURF2 knockdown results in a loss of tube formation ability in 
endothelial cells. (A) Tube formation showing that SMURF2 knockdown leads to a 
loss of tube formation ability, and is not rescued with chemical ROCK inhibition. (B) 
and (C) Quantitation of (A) showing that SMURF2 knockdown leads to substantially 
decreases in both mean tube area and mean tube length in HUVECs. 
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Figure 7.4: CCM2 knockdown leads to substantial changes in the kinome of 
HUVECs. ROCK and LIMK are enriched in shCCM2 cells. TIE-2 and BMX are highly 
depleted. TGFβ2 receptor is increased 
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Figure 7.5: Western blotting validating MIB-MS findings. (A) Total RhoA is increased 
in shCCM2 knockdown HUVECs. (B) CCM2 is highly knocked down in cells used in 
this experiment. (C) Total Tie2 is significantly decreased with loss of CCM2. (D) 
Phosphorylation of SMAD3 is decreased in CCM2 knockdown cells. 
 
 
 
 
 
 
 
 
VIII. Concluding remarks 
 
This work attempts to improve the understanding of the signaling networks 
involving the cerebral cavernous malformation proteins and shed light onto the 
molecular mechanism of this complex disease, with the ultimate goal of contributing 
to the development of an effective therapeutic strategy for CCM. We have 
demonstrated dysregulation of RhoA, a master regulator of the cytoskeleton in 
endothelial cells, and consequent downstream dysregulation of the critical ROCK 
signaling pathway. This work also shows the importance of the LIMK-cofilin pathway 
in CCM, demonstrating that hyperphosphorylation of cofilin is a biomarker in CCM, 
as well as the potential of endothelial progenitor-derived endothelial cells as a model 
system for studying CCM disease in humans. In vitro efficacy of ROCK inhibition in 
reversing the CCM phenotype and biochemical dysregulation resulting from loss of 
the CCM proteins has also been demonstrated, providing intriguing pre-clinical 
evidence for a potential pharmacological therapy. Finally, this work gives evidence 
for a molecular mechanism of CCM pathophysiology and provides a kinome wide-
look at the diverse effects of loss of the CCM proteins and subsequent GTPase 
dysregulation. 
Despite our recent advances, many pressing questions remain in CCM. We 
still do not know all the details of the molecular mechanism: how does this disease 
result from inactivation of any one of three seemingly unrelated scaffold proteins with 
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no known catalytic functions? The genetic mechanism of CCM development remains 
incompletely understood at best. How does the second genetic hit occur in familial 
patients? How is there homozygous inactivation of the CCM genes in sporadic 
patients? Are there really sporadic patients or is that an artifact of imprecise genetic 
testing? The CCM proteins are expressed throughout the body, and as shown by 
Uhlik et al., CCM2 is most highly expressed in macrophages. What are the roles of 
the CCM proteins in non-endothelial cells, and what roles do they play in normal 
human physiology? Do the CCM proteins contribute to cancer angiogenesis, and if 
so can they be targeted as part of cancer therapy? These and many more questions 
remain to be answered. 
While work goes on in the lab, we must not forget that CCM remains an 
incurable and relatively prevalent disorder with thousands of suffering patients in the 
United States and abroad that have not seen a change in the medical capability to 
treat their disease since their diagnosis. Basic science must go on so that we can 
rationally design therapeutic strategies and truly understand the biological role of 
CCM1, -2, and -3. Yet, a greater effort must be made in translational research and 
even clinical trials. Neurosurgeons and basic scientists must come together and 
collaborate on this disease. This is far easier said than done, even at excellent 
academic institutions like UNC, but clinicians are an integral part of the effort. This 
year marks the first, albeit phase 0 clinical study of a medical treatment for CCM, in 
this case the HMG-CoA Reductase inhibitor Simvastatin. While this is laudable, 
patients demand more. A phase 0 trial should certainly be initiated with the ROCK 
inhibitor Fasudil, which has been demonstrated to be safe and efficacious for 
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treatment of a related disorder in humans. Additionally, advances in technology must 
be applied to solving the puzzle of CCM. Progress in deep sequencing will allow for 
rapid and complete understanding of the mutations seen in CCM, allowing for 
increased molecular diagnostic capabilities for clinicians, and a better understanding 
of the biology of CCM mutations for researchers. MIB-MS and similar –omics 
technologies should be used to advance personalized medicine and fully understand 
the consequences of patient mutations. While much work remains, a 
pharmacological treatment for CCM appears increasingly possible. An increasing 
number of investigators and clinicians are devoting themselves to untangling the 
mysteries of this disease, and patient advocacy groups such as the Angioma 
Alliance are increasing awareness and funding locally and internationally. The future 
of CCM research is bright, and hopefully the next 5 years will see breakthroughs on 
the role of the CCM proteins in the human body and the availability of a 
pharmacologic therapeutic for CCM disease.
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